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 Genome-wide association study of diabetic kidney disease highlights biology involved in 
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 SIGNIFICANCE STATEMENT  
Diabetic kidney disease (DKD) is a devastating microvascular complication of both type 1 and 
type 2 diabetes. It has been shown to have a heritable component, but prior searches for the 
genetic determinants of this condition have had limited success. In this study, a new international 
genomics consortium (the Diabetic Nephropathy Collaborative Research Initiative, funded by the 
JDRF) has coalesced to assemble nearly 20,000 samples from participants with type 1 diabetes, 
with and without kidney disease. We report 16 new signals at genome-wide significance and begin 
to describe the genetic architecture of this globally relevant phenotype.  Our top signal centers on 
a protective missense coding variant at COL4A3, which encodes an integral component of the 
glomerular basement membrane that when mutated causes Alport syndrome.  
 
ABSTRACT  
Background: Diabetic kidney disease (DKD) is a heritable but poorly understood complication of 
diabetes. Methods: To identify genetic variants predisposing to DKD, we performed genome-
wide association analyses in 19,406 individuals with type 1 diabetes (T1D) using a spectrum of 
DKD definitions based on albuminuria and renal function. Results: We identified 16 genome-wide 
significant loci. The variant with the strongest association (rs55703767) is a common missense 
mutation in the collagen type IV alpha 3 chain (COL4A3) gene, which encodes a major structural 
component of the glomerular basement membrane (GBM) implicated in heritable nephropathies. 
The rs55703767 minor allele (Asp326Tyr) is protective against several definitions of DKD, 
including albuminuria and end-stage renal disease. Three other loci are in or near genes with 
known or suggestive involvement in DKD (BMP7) or renal biology (COLEC11 and DDR1). 
Conclusion: The 16 DKD-associated loci provide novel insights into the pathogenesis of DKD, 
identifying potential biological targets for prevention and treatment. 
 KEYWORDS 
Diabetic kidney disease, genome-wide association study, type 1 diabetes, genetics, diabetic 
complications, COL4A3 
 
  
  
 INTRODUCTION 
The devastating diabetic complication of diabetic kidney disease (DKD) is the major cause of end-
stage renal disease (ESRD) worldwide1,2. Current treatment strategies at best slow the 
progression of DKD, and do not halt or reverse the disease. Although improved glycemic control 
influences the rate of diabetic complications, a large portion of the variation in DKD susceptibility 
remains unexplained: one third of people with type 1 diabetes (T1D) develop DKD despite 
adequate glycemic control, while others maintain normal renal function despite long-term severe 
chronic hyperglycemia3.  
Though DKD demonstrates both familial clustering4-6 and single nucleotide polymorphism (SNP) 
heritability7, the specific genetic factors influencing DKD risk remain largely unknown. Recent 
genome-wide association studies (GWAS) have only identified a handful of loci for DKD, 
albuminuria, or estimated glomerular filtration rate (eGFR) in individuals with diabetes7-13. 
Potential reasons for the limited success include small sample sizes, modest genetic effects, and 
lack of consistency of phenotype definitions and statistical analyses across studies. Through 
collaboration within the JDRF Diabetes Nephropathy Collaborative Research Initiative (DNCRI), 
we adopted three approaches to improve our ability to find new genetic risk factors for DKD: 1) 
assembling a large collection of T1D cohorts with harmonized DKD phenotypes, 2) creating a 
comprehensive set of detailed DKD definitions, and 3) augmenting genotype data with low 
frequency and exome array variants.  
 
METHODS  
Cohorts and Phenotype Definitions. The GWAS meta-analysis included up to 19,406 patients 
with T1D of European origin from 17 cohorts (for study list and details see Table S1). All 
participants gave informed consent and all studies were approved by ethics committees from 
 participating institutions.  We defined a total of 10 different case-control outcomes to cover the 
different aspects of renal complications, using both albuminuria and eGFR (Figure 1). Five 
comparisons (“All vs. ctrl”, “Micro”, “DN”, “Macro”, and “ESRD vs. macro”) were based on 
albuminuria, measured by albumin excretion rate (AER) from overnight or 24-h urine collection, 
or by albumin creatinine ratio (ACR). Two out of three consecutive collections were required 
(when available) to classify the renal status of subjects as either normoalbuminuria, 
microalbuminuria, macroalbuminuria, or ESRD; for detailed thresholds, see Table S9. Controls 
with normal AER were required to have a minimum diabetes duration of 15 years; subjects with 
microalbuminuria/macroalbuminuria/ESRD were required to have minimum diabetes duration of 
5/10/10 years, respectively, to exclude renal complications of non-diabetic origins. Two 
comparisons (“ESRD vs. ctrl” and “ESRD vs. non-ESRD”) were based on presence of ESRD as 
defined by eGFR<15 mL/min or dialysis or renal transplant. Two phenotypes (“CKD” and “CKD 
extreme”) were defined based on eGFR estimated by the CKD-EPI formula: controls had eGFR 
≥60ml/min/1.73m2 for both phenotypes, and ≥15 years of diabetes duration; cases had eGFR 
<60ml/min/1.73m2 for the “CKD” phenotype, and eGFR <15 ml/min/1.73m2 or dialysis or renal 
transplant for the “CKD extreme” phenotype, and ≥10 years of diabetes duration. For the “CKD-
DN” phenotype that combined both albuminuria and eGFR data, controls were required to have 
both eGFR ≥60ml/min/1.73m2 and normoalbuminuria; cases had both eGFR <45ml/min/1.73m2 
and micro- or macroalbuminuria, or ESRD.  
GWAS Genotyping, Quality Control and Imputation. All study samples underwent genotyping, 
quality control (QC) and imputation centrally at the University of Virginia. In brief, samples were 
genotyped on the HumanCore BeadChip array (Illumina, San Diego, CA, USA), which contains 
~250,000 genome-wide tag SNPs and over 200,000 exome-focused variants. All samples were 
passed through a stringent QC protocol. Following initial genotype calling with Illumina software, 
all samples were re-called with zCall, a calling algorithm specifically designed for rare SNPs from 
 arrays. Variant orientation and position were aligned to hg19 (Genome Reference Consortium 
Human Build 37, GRCh37). Variant names were updated using 1000 Genomes as a reference. 
The data were then filtered for low quality variants (e.g. call rates <95% and excessive deviation 
from Hardy-Weinberg equilibrium) and samples (e.g. call rates <98%, gender mismatch, extreme 
heterozygosity). Principal Component Analysis (PCA) was performed separately for each cohort 
in order to empirically detect and exclude outliers with evidence of non-European ancestry (see 
supplement for full QC details, and Figure S1 for trait specific Manhattan and QQ plots). 
Genotypes were expanded to a total of approximately 49 million by imputation, using the minimac 
imputation tool14,15 and 1,000 Genomes Project (phase 3v5) as a reference. 
GWAS Analysis. A genome-wide association analysis was performed for each of the case-
control definitions under an additive genetic model, adjusting for age, sex, diabetes duration, 
study site (where applicable) and principal components. We conducted a second set of analyses 
adjusting for BMI and HbA1c which we refer to as our fully adjusted covariate model. Allele 
dosages were used to account for imputation uncertainty. Inverse-variance fixed effects meta-
analysis was performed using METAL and the following filters: INFO score >0.3, minor allele 
count >10 in both cases and controls, and presence of variant in at least two cohorts (Manhattan 
and QQ plots each trait and covariate model presented in Figure S1). The X chromosome was 
similarly analyzed for males and females both separately and in a combined analysis, with the 
exception of using hard call genotypes in place of allele dosages.16 We estimated the percentage 
of variance explained for all genome-wide significant SNPs across all disease definitions using 
the McKelvey-Zavoina17 pseudo-R2 statistic predicting continuous latent variables underlying 
binary outcomes.  
Glomerular basement membrane measurement in Renin-Angiotensin System Study 
(RASS). In brief, RASS was a double-blind placebo-controlled randomized trial of enalapril and 
losartan on renal pathology among 285 normoalbuminuric, normotensive subjects with T1D and 
 normal or increased measured glomerular filtration rate (>90 ml/min/1.73m2).18 Participants were 
followed for 5 years with percutaneous kidney biopsy completed prior to randomization and at 5 
years. Structural parameters measured by electron microscopy on biopsy included GBM width, 
measured by the electron microscopic orthogonal intercept method18. All RASS participants 
contributed DNA for genotyping.  
In silico replication in SUMMIT consortium. The SUMMIT consortium included up to 5,193 
European Ancestry subjects with type 2 diabetes (T2D), with and without kidney disease. In silico 
replication was performed on previously published GWAS on DKD with harmonized trait 
definitions for seven of our primary T1D analyses: “DN”, “Micro”, “Macro”, “ESRD”, “ESRD vs. 
non-ESRD”, “CKD”, and “CKD-DN” under an additive model, adjusting for age, gender and 
duration of diabetes.13 
RNAseq and microarray profiling of human kidney samples from the Pima cohort. Kidney 
biopsy samples from the Pima Indian cohort were manually micro-dissected into 119 glomerular 
and 100 tubule-interstitial tissues to generate gene expression profiles19. Expression profiling in 
the Pima Indian cohort kidney biopsies was carried out using Affymetrix GeneChip Human 
Genome U133 Array and U133Plus2 Array, as reported previously, and Affymetrix Human Gene 
ST Genechip 2.120,21, and on RNA-seq (Illumina). The libraries were prepared using the ClonTech 
SMARTSeq v4 Ultra Low Input polyA selection kit. Samples were sequenced on a HiSeq 4000, 
single end, 75bp. Mapping to human reference genome GRCh38.7 was performed with STAR 
2.5.2b (https://github.com/alexdobin/STAR). For annotation and quantification of mapping results 
we used cufflinks, cuffquant and cuffnorm in version 2.2.1 (https://cole-trapnell-
lab.github.io/cufflinks/). After mapping and quantification, PCA and Hierarchical Clustering was 
used to identify outliers and reiterated until no more outliers could be identified. 
RNA-sequencing and cis-eQTL analysis in human kidney samples from University of 
Pennsylvania cohort. Human kidney samples were obtained from surgical nephrectomies for a 
 total of 455 subjects with pathological data and were manually microdissected under a 
microscope in RNAlater for glomerular and tubular compartments (433 tubule and 335 glomerulus 
samples). The local renal pathologist performed an unbiased review of the tissue section by 
scoring multiple parameters, and RNA were prepared using RNAeasy mini columns (Qiagen, 
Valencia, CA) according to manufacturer's instructions.  
Whole kidney22, tubular and glomerular23 eQTL analyses have been described previously. Tubular 
and glomerular eQTL data sets were generated by 121 samples of tubules and 119 samples of 
glomeruli, respectively23. The cis window was defined as 1 megabase up- and down-stream of 
the transcriptional start site (±1Mb). Whole kidney cis-eQTL (further just referred to as eQTL) data 
set was generated from 96 human samples obtained from The Cancer Genome Atlas (TCGA) 
through the TCGA Data portal22.  
Mouse kidney single cell RNA-sequencing. Kidneys were harvested from 4 to 8-week-old male 
mice with C57BL/6 background and dissociated into single cell suspension as described in our 
previous study24. The single cell sequencing libraries were sequenced on an Illumina HiSeq with 
2x150 paired-end kit. The sequencing reads were demultiplexed, aligned to the mouse genome 
(mm10) and processed to generate gene-cell data matrix using Cell Ranger 1.3 
(http://10xgenomics.com)24. 
Genomic features of human kidney. Human kidney-specific chromatin immunoprecipitation 
followed by sequencing (ChIP-seq) data can be found at GEO: GSM621634, GSM670025, 
GSM621648, GSM772811, GSM621651, GSM1112806, GSM621638. Different histone markers 
were combined into chromatin states using ChromHMM25. 
Gene and gene set analysis. PASCAL and MAGMA (v1.06) gene and pathway scores were 
conducted on all 20 sets of GWAS summary statistics using default pathway libraries from 
BioCarta, REACTOME, and KEGG. MAGENTA (vs2, July 2011) pathway analysis included 4725 
pathways with a minimum of five genes within the gene set for the 10 standard adjustment models. 
 We conducted DEPICT individually on all 20 sets of GWAS summary statistics with P<10-5 and 
additional pooled analyses using genome-wide minimum P-values from: 1) All 20 analyses (10 
phenotypes and 2 covariate models) and 2) 16 analyses of the 8 most related phenotypes which 
excluded ESRD vs Macro and Micro.  
Transcriptome-wide association study (TWAS): TWAS of kidney glomeruli and tubuli was 
performed using MetaXcan with default parameters,26 based on eQTL data for human glomerular 
and tubular cells.23 
 
RESULTS 
Phenotypic comparisons 
We investigated a broad spectrum of DKD definitions based on albuminuria and renal function 
criteria, defining a total of 10 different case-control comparisons to cover the different aspects of 
disease progression (Figure 1). Seven comparisons were based on albuminuria and/or ESRD 
(including diabetic nephropathy [DN], defined as either macroalbuminuria or ESRD); two were 
defined based on eGFR (used to classify severity of chronic kidney disease [CKD]); and one 
combined both albuminuria and eGFR data (“CKD-DN”). Each phenotypic definition was analyzed 
separately in GWAS; to account for the 10 definitions each analyzed under two covariate 
adjustment models, we estimated16 the total effectively independent tests as 7.4, allowing us to 
compute a more conservative study-wide significance threshold (P<6.76×10-9), based on 
genome-wide significance (P<5×10-8) and Bonferroni correction for 7.4 effective tests. 
Top genome-wide association results highlight COL4A3 
GWAS meta-analysis included association results for up to 19,406 individuals with T1D of 
European descent from 17 cohorts for the 10 case-control definitions (Table S1). We identified 
16 novel independent loci that achieved genome-wide significance (P<5×10-8) in either the 
minimal or fully adjusted models, in which four lead SNPs also surpassed our more conservative 
 study-wide significance threshold (Table 1; Figure 2, Manhattan plot; Figures S2a-p, regional 
association and forest plots). None of the loci reaching genome-wide significance have been 
previously identified in GWAS or candidate gene studies for DKD or closely related traits. All SNPs 
with minor allele frequency greater than 1% explain 2.5% and 3.0% of the total variance 
(McKelvey-Zavoina17 pseudo-R2) of DN after adjusting for covariates in the minimal and full 
covariate models, respectively (Table S12).  
The strongest signal was rs55703767 (minor allele frequency [MAF]=0.21), a common missense 
variant (G>T; Asp326Tyr) in exon 17 of COL4A3. This SNP was associated with protection from 
DN (odds ratio [OR]=0.79, P=5.34×10-12), any albuminuria (OR=0.84, P=3.88×10-10), the 
combined CKD-DN phenotype (OR =0.77, P=5.30×10-9), and macroalbuminuria (OR=0.79, 
P=9.28×10-9). Interestingly, we found that rs55703767 in COL4A3 was more strongly associated 
in men (OR=0.73, P=1.29×10-11) than in women (OR=0.85, P=1.39×10-3; Phet=1.58×10-2). 
COL4A3 encodes the alpha 3 chain of collagen type IV, a major structural component of the 
GBM27.  
COL4A3 variation and kidney phenotypes 
In persons with T1D and normoalbuminuria, GBM width predicts progression to proteinuria and 
ESRD independently of glycated hemoglobin (HbA1c)28. We examined the influence of the 
COL4A3 variant on GBM width in 253 RASS18 participants with T1D and normal AER, eGFR (>90 
ml/min/1.73 m2) and blood pressure, who had biopsy and genetic data (Table S2). The DKD-
protective minor T allele was associated with 19.7 nm lower GBM width (standard error (SE) 8.2 
nm, P=0.02), with the lowest mean GBM width among TT homozygotes (Figure 3; Table S3), 
after adjusting for age, sex, and diabetes duration, and without detectable interactions with T1D 
duration or mean HbA1c. Thus, the protective T allele carriers had thinner GBM prior to any renal 
complications.  
 We did not detect any eQTL association between rs55703767 and COL4A3 expression in mouse 
glomeruli or in human tissues, and thus assume that the variant affects the COL4A3 structure 
rather than expression levels. Nevertheless in a Pima Indian cohort of 97 subjects with DKD with 
morphometric and expression data from renal biopsies, COL4A3 expression was negatively 
correlated with the GBM surface density (filtration surface density) (β=-0.27, P=0.02), which is 
associated with eGFR in DKD in both T1D and T2D29,30. Furthermore, in 335 micro-dissected 
human glomerulus samples, expression of COL4A3 was negatively correlated with 
glomerulosclerosis, potentially reflecting podocyte depletion in sclerotic glomeruli (corr=0.16, 
P=4.8×10-3; Figure S3). COL4A3 expression in glomeruli, but not in tubules, was also nominally 
correlated with eGFR (corr 0.108, P=0.047; Figure S3). 
Evidence for hyperglycemia specificity 
Hyperglylcemia promotes the development of diabetic complications. If a genetic variant exerts a 
stronger effect in the setting of hyperglycemia, 1) it might not be detected in general CKD, 2) it 
may be detected whether hyperglycemia is conferred by T1D or T2D, 3) its effect may be stronger 
at higher glycemic strata, and 4) interventions that reduce glycemia may attenuate the association 
signal. COL4A3 rs55703767 was not associated with eGFR in a general population sample of 
110,517 mainly non-diabetic participants of European ancestry31 (Table S4). However, in a 
smaller cohort of 5,190 participants with T2D and DKD phenotypes in the SUrrogate markers for 
Micro- and Macro-vascular hard endpoints for Innovative diabetes Tools (SUMMIT) consortium, 
we detected a directionally consistent suggestive association of COL4A3 rs55703767 with DN (2-
tailed P=0.08; Table S5).  
We further stratified the association analyses by HbA1c in the Finnish Diabetic Nephropathy 
(FinnDiane) Study, a T1D cohort study with extensive longitudinal phenotypic data32. Based on 
the time-weighted mean of all available HbA1c measurements for each individual, 1,344 
individuals had mean HbA1c <7.5% (58 mmol/mol), and 2,977 with mean HbA1c ≥7.5%. COL4A3 
 rs55703767 was nominally significant (P<0.05) only in individuals with HbA1c ≥7.5% (Figure 4, 
Table S6, Figure S4). However, the interaction between HbA1c and COL4A3 rs55703767 was 
not significant (P=0.83). Upon further examination, the genetic effect was diminished also in the 
highest HbA1c quartile (>9.3%), as the environmental effect of HbA1c seems to overwhelm any 
potential genetic effects at COL4A3 (test of heterogeneity non-significant). In a similar setting of 
individuals with T2D from the GoDARTS study (N=3226)13,33, no difference was observed for 
COL4A3 rs55703767 between HbA1c strata below or above 7.5% (Figure S5). We performed a 
similar HbA1c stratified analysis in the Diabetes Control and Complications Trial (DCCT), whose 
participants, all with T1D, continue to be followed in the Epidemiology of Diabetes Interventions 
and Complications (EDIC)34,35. In DCCT-EDIC the effect of COL4A3 rs55703767 was stronger 
among those recruited in the secondary cohort (mild retinopathy and longer diabetes duration at 
baseline) who were originally randomized to conventional treatment and therefore had higher 
HbA1c than the intensive treatment group (Table S7). Taken together, these independent lines 
of evidence strongly suggest that the COL4A3 variant effect on DKD risk is amplified by poor 
glycemic control. 
Other association signals 
A comprehensive list of all loci that achieved genome-wide significance from either the minimal 
or the fully adjusted covariate models is reported in Table 1. The fewer covariates required for the 
minimal model results in improved statistical power due to fewer subjects with missing data, 
whereas the fully adjusted model allows the identification of associations potentially mediated by 
covariates. Comparison of the adjustment models revealed strong consistency between the two 
models (Figure S6). Table 1 is stratified into two sets of loci: common and/or known kidney biology 
loci (top half, n=8) and uncommon and no known kidney biology loci (bottom half, n=8). We focus 
on loci in the top half of the table, common and/or in/near genes with relevant kidney biology.  
 Two other genome-wide significant signals were near genes encoding proteins related to 
collagen. Variant rs12615970 (MAF=0.13), located 53 kb downstream of COLEC11, was 
associated with CKD (OR=1.31, P=9.43×10-9), and rs116772905 (MAF=0.011) in exon 14 of 
DDR1 was associated with microalbuminuria (OR=3.78, P=4.40×10-8). rs116772905 is in perfect 
linkage disequilibrium with rs118124843, the lead association with microalbuminuria for this locus 
under the full adjustment model (taking into account both BMI and HbA1c), located 29 kb 
downstream of DDR1 (OR=3.97, P=3.37×10-8). COLEC11 encodes a collectin protein containing 
both a collagen-like domain and a carbohydrate recognition domain for binding sugars, and DDR1 
encodes the discoidin domain-containing receptor 1, which binds collagens including type IV 
collagen. 
In addition to COL4A3 rs55703767, three other low-frequency variants achieved study-wide 
significance (P<6.76×10-9), each associated with microalbuminuria: rs142823282 (MAF=0.017), 
22 kb upstream of TAMM41 encoding a mitochondrial translocator assembly and maintenance 
protein36,37 (OR=6.75, P=1.13×10-11), rs144434404 (MAF=0.011), in intron 1 of BMP7 encoding 
the bone morphogenetic protein 7 previously implicated in DKD38 (OR=6.75, P=2.67×10-9), and 
rs145681168 (MAF=0.014), in intron 3 of two transcripts of HAND2 antisense RNA 1 (HAND2-
AS1; OR=5.53, P=5.40×10-9) and 50 kb upstream of HAND2, encoding a heart and neural crest 
derivatives transcription factor.  
Two additional common variants achieved genome-wide significance: rs551191707 (MAF=0.122) 
in PRNCR1 associated with ESRD when compared with macroalbuminuria (OR=1.70, 
P=4.39×10-8) and rs61983410 (MAF=0.213) in an intergenic region on chromosome 14 
associated with microalbuminuria (full model OR=0.78, P=3.06×10-8). The remaining seven 
variants associated with features of DKD had lower allele frequencies (four with 0.01≤MAF≤0.05 
and four with MAF<0.01) and did not achieve study-wide significance.  
 As we had done for COL4A3 rs55703767, we tested whether the associations of the 15 other 
variants were amplified by hyperglycemia. None of the 15 variants were significantly associated 
with eGFR in the general population (Table S4). In the smaller SUMMIT T2D cohort13 we were 
able to interrogate seven loci with comparable trait definitions. The odds ratios were directionally 
consistent in six of them (binomial sign test: P=0.0625, Table S5). In FinnDiane seven of the 
remaining 15 loci were observed with sufficient frequency (minor allele counts >10) to allow 
subgroup analysis. Two additional SNPs (rs149641852 in SNCAIP and rs12615970 near 
COLEC11) were nominally significant (P<0.05) only in individuals with HbA1c ≥7.5%, however 
the genotype × HbA1c interaction term was non-significant (Table S6, Figure S4). 
Variants previously associated with DKD  
We investigated the effect of variants previously associated at genome-wide significance with 
renal complications in individuals with diabetes8-13,39. Across the ten sub-phenotypes in our meta-
analysis, we found evidence of association for seven of nine examined loci (P<0.05, Figure S7): 
We replicated two loci that were previously discovered without overlapping individuals with the 
current study: SCAF8/CNKSR3 rs12523822, originally associated with DKD (P=6.8×10-4 for “All 
vs ctrl”) 8; and UMOD rs77924615, originally associated with eGFR in both individuals with and 
without diabetes (P=5.2×10-4 for “CKD”)31. Associations at the AFF3, RGMA-MCTP2, and ERBB4 
loci, identified in the GEnetics of Nephropathy—an International Effort (GENIE) consortium12, 
comprised of a subset of studies included in this current effort, remained associated with DKD, 
though the associations were attenuated in this larger dataset (RGMA-MCTP2 rs12437854 
P=2.97×10-5; AFF3 rs7583877 P=5.97×10-4; ERBB4 rs7588550 P=3.53×10-5; Figure S8). 
Associations were also observed at the CDCA7/SP3 (rs4972593, P=0.020 for “CKD-DN”, 
originally for ESRD exclusively in women11) and GLRA3 (rs1564939, P=0.016 for “CKD 
extremes”, originally for AER10,39), but these analyses also include individuals that overlap with 
the original studies. Apart from the UMOD locus, none of the 63 loci associated with eGFR in the 
 general population31 were associated with DKD after correction for multiple testing (P<7.0×10-4, 
Figure S9). 
Gene and gene set analysis 
We conducted gene-level analyses by employing two methods that aggregate SNP summary 
statistics over a gene region while accounting for linkage disequilibrium, MAGMA and 
PASCAL40,41. MAGMA identified five genes at a Bonferroni-corrected threshold (P<0.05/18,222 
genes tested = 2.74×10-6): the collagen gene COL20A1 associated with “CKD extreme” (full 
model P=5.77×10-7) and “ESRD vs. non-ESRD” (full model P=9.53×10-7), SLC46A2 associated 
with “All vs. ctrl” (P=7.38×10-7), SFXN4 associated with “Macro” (full model P=1.65×10-7), GLT6D1 
associated with “ESRD vs. macro” (P=1.49×10-6), and SNX30 associated with “All vs ctrl” 
(P=2.49×10-6) (Table S8). Although PASCAL did not identify any significant gene level 
associations, the five MAGMA-identified genes had P<5.0×10-4 in PASCAL (Table S9). Both 
SFXN4 and CBX8 have been reported to be differentially methylated in patients with diabetes 
with and without nephropathy42,43.  
Additionally, we used MAGMA, PASCAL, DEPICT, and MAGENTA to conduct gene-set analysis 
in our GWAS dataset. The four methods identified 12 significantly enriched gene sets (Table 
S10). One gene set, “negative regulators of RIG-I MDA5 signaling” was identified in two different 
pathway analyses (MAGMA and PASCAL) of our fully adjusted GWAS of ESRD vs. Macro. 
Several additional related and overlapping gene sets were identified, including “RIGI MDA5 
mediated induction of IFN alpha beta pathways”, “TRAF3 dependent IRF activation pathway”, and 
“TRAF6 mediated IRF activation” (PASCAL) and “activated TLR4 signaling” (MAGENTA). RIG-I, 
MDA5 and the toll-like receptor TLR4 are members of the innate immune response system that 
respond to both cellular injury and infection44,45 and transduce highly intertwined signaling 
cascades. These include the signaling molecules TRAF3 and TRAF6, which induce expression 
of type I interferons and proinflammatory cytokines implicated in the progression of DKD46,47. 
 Specifically, the TLR4 receptor and several of its ligands and downstream cytokines display 
differential levels of expression in DKD renal tubules vs. normal kidneys and vs. non-diabetic 
kidney disease controls48, and TLR4 knockout mice are protected from DKD and display marked 
reductions in interstitial collagen deposition in the kidney49. Other pathways of interest include 
“other lipid, fatty acid and steroid metabolism”, “nitric oxide signaling in the cardiovascular 
system”, and “Tumor necrosis factor (TNF) family member”, with both nitric oxide and TNF-𝛼 
implicated in DKD50,51,52. 
Expression and epigenetic analyses 
We interrogated gene expression datasets in relevant tissues to determine whether our top 
signals underlie expression quantitative trait loci (eQTL). We first analyzed genotype and RNAseq 
gene expression data from 96 whole human kidney cortical samples22 and micro-dissected human 
kidney samples (121 tubule and 119 glomerular samples)23 from subjects of European descent 
without any evidence of renal disease (Figure S10). No findings in this data set achieved 
significance after correction for multiple testing. In the GTEx and eQTLgen datasets, COL4A3 
rs55703767 had a significant eQTL (P=5.63×10-38) with the MFF gene in blood, but is most likely 
due to modest LD with other nearby strong eQTLs in the region. rs118124843 near DDR1 and 
VARS2 had multiple significant eQTLs in blood besides VARS2 (P=1.71×10-5; Table S11). 
Interestingly, rs142823282 near TAMM41 was a cis-eQTL for PPARG (P=4.60×10-7), a 
transcription factor regulating adipocyte development, glucose and lipid metabolism; PPARγ 
agonists have been suggested to prevent DKD53.  
To ascertain the potential functional role of our top non-coding signals, we mined ChIP-seq data 
derived from healthy adult human kidney samples25. SNP rs142823282 near TAMM41 was 
located close to kidney histone marks H3K27ac, H3K9ac, H3K4me1, and H3K4me3, suggesting 
that this is an active regulator of TAMM41 or another nearby gene (Figure S11). Interestingly, in 
 recent work we have shown that DNA methylation profiles in participants with T1D with/without 
kidney disease show the greatest differences in methylation sites near TAMM4154.  
To establish whether the expression of our top genes shows enrichment in a specific kidney cell 
type, we queried an expression dataset of ~50,000 single cells obtained from mouse kidneys24. 
Expression was detected for six genes in the mouse kidney atlas: three (COL4A3, SNCAIP, and 
BMP7) were almost exclusively expressed in podocytes (Figure 5), supporting the significant role 
for podocytes in DKD.  
Gene expression levels in kidneys in cases vs. controls were predicted with TWAS based on the 
GWAS summary statistics and eQTL data of kidney glomeruli and tubuli.23 While none of the 
genes survived correction for multiple testing, analysis suggested 18 genes with differential 
expression in cases and controls with P<1×10-4, including the NPNT, PRRC2C, and VPS33B 
genes (Table S12). NPNT encodes for nephronectin, an extra-cellular matrix protein on GBM. 
Knocking out NPNT or decreasing NPNT expression levels have been shown to induce podocyte 
injury related to GBM.55 On the contrary, TWAS predicted higher NPNT expression within DN 
cases vs. normal AER. In line with our TWAS finding, NPNT is significantly upregulated in 
glomeruli of diabetic nephropathy mouse model vs. non-diabetic mouse (p=6.4x10-4, fold change 
1.3, in top 2%, accessed through www.neproseq.org).56 Furthermore, a variant near PRRC2C 
was recently associated with albuminuria in the UK Biobank,57 and rare mutations in VPS33B 
gene cause arthrogryposis, renal dysfunction, and cholestasis-1 (ARCS1) syndrome involving 
proximal–tubular dysfunction and usually death by the age of 1.58 
 
DISCUSSION 
Our genome-wide analysis of 19,406 participants with T1D identified 16 genome-wide significant 
loci associated with DKD, four of which remained significant after a conservative correction for 
multiple testing. Four of the 16 genome-wide significant signals are in or near genes with known 
 or suggestive biology related to renal function/collagen (COL4A3, BMP7, COLEC11, and DDR1), 
but this is the first time that naturally occurring variation (MAF > 1%) in these loci has been 
associated with DKD. Our most significant signal was a protective missense variant in COL4A3, 
rs55703767, reaching both genome-wide and study-wide significance with multiple definitions of 
DKD. Moreover, this variant demonstrated a significant association with GBM width such that 
protective allele carriers had thinner GBM before any signs of kidney disease, and its effect was 
dependent on glycemia.  
COL4A3, with COL4A4 and COL4A5, make up the so-called “novel chains” of type IV collagen59, 
which together play both structural and signaling roles in the GBM. Specifically, COL4A3 is known 
to bind a number of molecules including integrins, heparin and heparin sulfate proteoglycans, and 
other components of the GBM such as laminin and nidogen. These interactions mediate the 
contact between cells and the underlying collagen IV basement membrane, and regulate various 
processes essential to embryonic development and normal physiology including cell adhesion, 
proliferation, survival and differentiation. Dysregulation of these interactions has been implicated 
in several pathological conditions including CKD60.  
Mutations in COL4A3 are responsible for the autosomal recessive form of Alport syndrome, a 
progressive inherited nephropathy, as well as benign familial hematuria, characterized by thin (or 
variable width) GBM, and thought to be a milder form of Alport syndrome61. Furthermore, 
mutations in COL4A3 have also been identified in patients with focal segmental 
glomerulosclerosis (FSGS), often leading to proteinuria and renal failure. Some of these patients 
with FSGS presented with segmental GBM thinning.62 Of note, the common rs55703767 
(COL4A3 Asp326Tyr) variant, protecting from DKD, was also associated with thinner GBM in 
individuals with diabetes but without renal complications, a feature that seems to be beneficial in 
the context of diabetes. The rs55703767 SNP is predicted to alter the third amino acid of the 
canonical triple-helical domain sequence of Glycine (G)-X-Y (where X and Y are often proline (P) 
 and hydroxyproline (Y), respectively) from G-E-D (D=Aspartic) to G-E-Y63, potentially impacting 
the structure of the collagen complex. In addition, a recent study64 of candidate genes involved in 
renal structure reported rs34505188 in COL4A3 (not in linkage disequilibrium with rs55703767, 
r2=0.0006) to be associated with ESRD in African Americans with T2D (MAF=2%, OR=1.55, 
P=5×10-4). Together with the trend towards association we have seen in SUMMIT and the 
glycemic interaction we have reported here, these findings suggest variation in COL4A3 may be 
associated with DKD in T2D as well. 
Given its association as a protective SNP, we can speculate that the rs55703767 variant may 
confer tensile strength or flexibility to the GBM, which may be of particular relevance in the 
glomerular hypertension associated with DKD. Alternatively, COL4A3 may regulate the rates of 
production and/or turnover of other GBM components, affecting GBM width changes in diabetes. 
How these effects might confer protection in a manner dependent on ambient glucose 
concentrations is unknown. Future mechanistic studies will be required to determine the precise 
role of this variant in DKD; elucidation of its interaction with glycemia in providing protection might 
be relevant to other molecules implicated in diabetic complications. 
In keeping with the collagen pathway, the synonymous exonic variant rs118124843, which 
reached genome-wide significance for the “Micro” phenotype, is located near DDR1, the gene 
encoding the discoidin domain-containing receptor 1. Based on chromatin conformation 
interaction data from Capture HiC Plotter (CHiCP),65 the rs118124843 containing fragment 
interacts with six gene promoter regions, including DDR1, suggesting that the variant regulates 
DDR1 expression across multiple tissues (Table S11). DDR1 is a collagen receptor66 shown to 
bind type IV collagen67, and is highly expressed in kidneys, particularly upon renal injury68. Upon 
renal injury, Ddr1-deficient mice display lower levels of collagen69, decreased proteinuria, and an 
increased survival rate compared to wild-type controls70, with Ddr1/Col4a3 double knockout mice 
displaying protection from progressive renal fibrosis and prolonged lifespan compared to Col4a3 
 knockout mice alone69. Thus, through its role in collagen binding DDR1 has been suggested as a 
possible therapeutic target for kidney disease69.  
The association of rs12615970, an intronic variant on chromosome 2 near the COLEC11 gene, 
met genome-wide significance for the CKD phenotype, as well as nominal significance for multiple 
albuminuria-based traits. The rs12615970 containing fragment was found to interact with 
COLEC11, ALLC, and ADI1 transcription start sites in chromatin conformation data on GM12878 
cell line (Table S11)65,71. Collectin-11 is an innate immune factor synthesized by multiple cell 
types, including renal epithelial cells with a role in pattern recognition and host defense against 
invasive pathogens, through binding to fructose and mannose sugar moieties72,73. Mice with 
kidney-specific deficiency of COLEC11 are protected against ischemia-induced tubule injury due 
to reduced complement deposition74, and mutations in COLEC11 have been identified in families 
with 3MC syndrome, a series of rare autosomal recessive disorders resulting in birth defects and 
abnormal development, including kidney abnormalities75. 
The intronic variant rs144434404, associated at study-wide significance with the 
microalbuminuria phenotype, resides within the bone morphogenetic protein 7 (BMP7) gene. 
BMP7 encodes a secreted ligand of the transforming growth factor-beta superfamily of proteins. 
Developmental processes are regulated by the BMP family of glycosylated extracellular matrix 
molecules, via serine/threonine kinase receptors and canonical Smad pathway signaling. 
Coordinated regulation of both BMP and BMP-antagonist expression is essential for developing 
tissues, and changes in the levels of either BMP or BMP-antagonists can contribute to disease 
progression such as fibrosis and cancer76. BMP7 is required for renal morphogenesis, and Bmp7 
knockout mice die soon after birth due to reduced ureteric bud branching77-79. Maintenance of 
Bmp7 expression in glomerular podocytes and proximal tubules of diabetic mice prevents 
podocyte loss and reduces overall diabetic renal injury38. More recently, we have identified a 
mechanism through which BMP7 orchestrates renal protection through Akt inhibition and 
 highlights Akt inhibitors as potential anti-fibrotic therapeutics80. It is also noteworthy that the BMP7 
antagonist grem-1 is implicated in DKD81-83 and gremlin has been implicated as a biomarker of 
kidney disease84.  
Strengths of this analysis include the large sample size, triple that of the previous largest GWAS; 
the uniform genotyping and quality control procedures; standardized imputation for all studies 
(1,000 Genomes reference panel); the inclusion of exome array content; the exploration of 
multiple standardized phenotype definitions of DKD; and supportive data from various sources of 
human kidney samples. Several of the loci identified have known correlations with kidney biology, 
suggesting that these are likely true associations with DKD. However, we acknowledge a number 
of limitations. First, nine variants have low MAF and were driven by only two cohorts, indicating 
that further validation will be required to increase confidence in these associations. Second, seven 
variants were significantly associated with microalbuminuria only, a trait shown to be less heritable 
in previous studies. We included these loci to maximize comprehensiveness in reporting novel 
DKD associations. Replication in independent samples and functional confirmation is required to 
validate all of these loci. Even though the gene-level, gene set and pathway analyses had limited 
power, these analyses identified several additional potential DKD loci and pathways, some with 
relevance to kidney biology, that require further follow-up. Finally, while we included only controls 
with a minimum diabetes duration of 15 years, we cannot fully rule out that some of the controls 
would progress to DKD in the future, as the improvements in diabetes treatment in the last 
decades have postponed the onset of complications. We also excluded cases with short diabetes 
duration to avoid renal complications that might be due to other causes. These phenotypic 
definitions were meant to overcome the limitation that in clinical practice kidney biopsies are rarely 
taken from individuals with diabetes to verify the diagnosis. As for any late onset disease, these 
challenges in phenotypic definition may have reduced our power to detect additional associations. 
We note, however, that this relatively small degree of contamination would lead to loss of power 
 and increased type II error rather than false positive findings; therefore, it does not undermine the 
robustness of the associations reported here. 
Diabetic complications are unquestionably driven by hyperglycemia and partially prevented by 
improved glycemic control in both T1D and T2D, but there has been doubt over what contribution, 
if any, inherited factors contribute to disease risk. In line with previous genetic studies, this study 
with a markedly expanded sample size identified several loci strongly associated with DKD risk. 
These findings suggest that larger studies, aided by novel analyses and including T2D, will 
continue to enhance our understanding of the complex pathogenesis of DKD, paving the way for 
molecularly targeted preventive or therapeutic interventions. 
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TABLES  
Table 1. Loci associated with DKD at study-wide (P<6.76×10-9, bold) and genome-wide (P<5×10-8) significance.  
Common variants and/or genes with relevant kidney biology are reported in the top half of the table. Uncommon variants 
(MAF < 2%) with no known relevant kidney biology are reported in the bottom half of the table. Genes are annotated as 
follows: missense variant in the indicated gene (M); intronic, synonymous, or noncoding variant in the indicated gene (G); gene 
nearest to lead variant (N); gene has relevant kidney (B). Chr, chromosome; pos, position; EAF, effect allele frequency; OR, odds 
ratio; min, minimally adjusted covariate model; full, fully adjusted covariate model. 
 
SNP Chr:pos 
Effect 
allele 
Other 
allele 
EAF 
Notable 
gene(s) 
Phenotype ORmin P-valuemin ORfull P-valuefull 
rs55703767 2:228121101 T G 0.206 
COL4A3 
(M, B, N) 
DN 0.79 5.34×10-12 0.78 8.19×10-11 
            All vs. ctrl 0.83 3.88×10-10 0.84 9.68×10-9 
            CKD+DN 0.77 5.30×10-9 0.76 3.77×10-8 
            Macro 0.78 9.28×10-9 0.77 9.38×10-9 
rs12615970 2:3745215 G A 0.133 
COLEC11 (B) 
ALLC (N, G) 
CKD 0.76 9.43×10-9 0.77 1.60×10-7 
rs142823282 3:11910635 G A 0.011 
TAMM41 
(N, B) 
Micro 6.73 8.32×10-10 9.18 1.13×10-11 
rs145681168 4:174500806 G A 0.014 
HAND2-AS1  
(N, G, B)  
Micro 5.53 2.06×10-7 7.47 5.40×10-9 
rs118124843 6:30887465 T C 0.011 
DDR1 (B) 
VARS2 (G) 
Micro 3.79 4.42×10-8 3.99 3.37×10-8 
rs77273076 7:99728546 T C 0.008 
MBLAC1 
(N, B) 
Micro 9.16 1.04×10-8 7.10  2.28×10-7 
rs551191707 8:128100029 CA C 0.122 
PRNCR1 
(N) 
ESRD vs. 
macro 
1.70 4.39×10-8 1.71 3.15×10-6 
rs61983410 14:26004712 T C 0.213 
STXBP6 
(N) 
Micro 0.79 9.84×10-8 0.78 3.06×10-8 
rs144434404 20:55837263 T C 0.011 
BMP7 
(N, G, B) 
Micro 6.78 2.67×10-9 6.66 4.65×10-9 
                      
 39 
rs115061173 3:926345 A T 0.014 
LINC01266 
(N) 
ESRD vs. 
ctrl 
9.40 4.07×10-8 8.34 4.08×10-5 
rs116216059 3:36566312 A C 0.016 
STAC 
(N, G) 
ESRD vs.  
non-ESRD 
8.73 1.37×10-8 11.78 1.41×10-4 
rs191449639 4:71358776 A T 0.005 
MUC7 
(N) 
DN 32.42 1.32×10-8 32.47 2.09×10-8 
rs149641852 5:121774582 T G 0.012 
SNCAIP 
(N, G) 
CKD 
extreme 
9.01 1.37×10-8 --- --- 
rs183937294 11:16937846 G T 0.007 
PLEKHA7 
(N, G) 
Micro 17.22 1.65×10-8 23.62 2.10×10-6 
rs113554206 14:73740250 A G 0.012 
PAPLN 
(N, G) 
Macro 4.60 5.39×10-7 10.42 8.46×10-9 
rs185299109 18:1811108 T C 0.007 intergenic CKD 20.75 1.28×10-8 44.75 4.99×10-7 
 
 
 
 
 
Figure 1
Figure 1. Phenotypic analysis of DKD. Schematic diagram of outcomes 
analyzed in this study. Numbers indicate the total number of cases (darker 
gray) and controls (lighter gray) included in the meta-analyses for each 
phenotype. Microalb.: microalbuminuria; macroalb.: macroalbuminuria; 
eGFR: estimated glomerular filtration rate; ESRD: End-stage renal disease, 
defined as eGFR <15 mL/min/1.73m2 or undergoing dialysis or having renal 
transplant; CKD: chronic kidney disease.
Figure 2
Figure 2 Genome-wide association testing of all 10 phenotypic
comparisons. Multiphenotype Manhattan plot shows lowest P-value at
each marker for each of the 10 phenotypic comparisons, under the standard
and fully-adjusted model. Significance of SNPs (-log10[P-value], y axis) is
plotted against genomic location (x axis). Loci surpassing genome-wide
significance (red line) and/or study-wide significance (blue line) are colored
by phenotype.
Figure 3
Figure 3. Adjusted residuals of GBM width by rs55703767 genotype 
and sex. Box and whisker plot of residuals of mean GBM width after 
adjusting for age, sex, and diabetes duration, stratified by GG, GT, or TT 
genotype at rs55703767, with overlay of individual data points for both 
females (pink) and males (blue).
Figure 4
Figure 4. Association at rs55703767 (COL4A3) stratified by HbA1c below 
or above 7.5%, for the phenotypes reaching genome-wide significance 
in the combined meta-analysis. Analysis included 1344 individuals with 
time-weighted mean HbA1c <7.5% (58 mmol/mol), and 2977 with mean 
HbA1c ≥7.5% from the FinnDiane study; the individuals had median 19 
HbA1c measurements (range 1 – 129).  
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Figure 5
COL4A3
SNCAIP
BMP7
PLEKHA7
VARS2
DDR1
nCells %
1,001 2.29 Endo
78 0.18 Podo
26,482 60.54 PT
1,581 3.61 LOH
8,544 19.53 DCT
870 1.99 CD-PC
1,729 3.95 CD-IC
549 1.26 Fib
228 0.52 Macro
74 0.17 Neutro
235 0.54 B lymph
1,308 2.99 T lymph
313 0.72 NK
Figure 5. Single cell RNA-sequencing in mouse kidney shows COL4A3, 
SNCAIP, and BMP7 are specifically expressed in podocytes. Mean 
expression values of the genes were calculated in each cluster. The color 
scheme is based on z-score distribution; the map shows genes with z-
score>2. In the heatmap, each row represents one gene and each column is 
single cell type. Percentages of assigned cell types are summarized in the 
right panel. Endo, containing endothelial, vascular, and descending loop of 
Henle; Podo, podocyte; PT, proximal tubule; LOH, ascending loop of Henle; 
DCT, distal convoluted tubule; CD-PC, collecting duct principal cell; CD-IC, 
collecting duct intercalated cell; CD-Trans, collecting duct transitional cell; 
Fib, fibroblast; Macro, macrophage; Neutro, neutrophil; lymph, lymphocyte; 
NK, natural killer cell.
GWAS of DKD Supplement 
1 
SUPPLEMENTAL INFORMATION 
Contents 
SUPPLEMENTAL METHODS. .............................................................................................. 3 
Table S1. Cohorts contributing to analyses. ...................................................................... 12 
Table S2. Characteristics of RASS participants. Categorical variables display counts 
and percentage. Continuous values are mean ± standard deviation. ........................... 12 
Table S3. Multivariate analysis of association between rs55703767 and GBM width 13 
Table S4: Look-up of the lead loci in GWAS on eGFR in the general population 
(Gorski et al., 2017).33 ........................................................................................................... 14 
Table S5: Look-up of the lead loci in GWAS in the SUMMIT consortium (van Zuydam 
et al., 2018).23 .......................................................................................................................... 15 
Table S6: Association at lead loci stratified by HbA1c <7.5%. ....................................... 16 
Table S7. Association of rs55703767 with DN in DCCT/EDIC subgroups. .................. 17 
Table S8. Significant (P<0.05/18,222 genes tested = 2.74 × 10-6) gene level 
associations with diabetic kidney disease in MAGMA. .................................................... 18 
Table S9. Top nominally significant gene level associations (P < 1.0 x 10-5) with 
diabetic kidney disease in PASCAL. ................................................................................... 18 
Table S10: Significant gene set and pathway analysis results. ...................................... 19 
Table S11. eQTL associations and chromatin conformation interactions for the lead 
SNPs. ....................................................................................................................................... 20 
Table S12: Transcriptome-wide association analysis (TWAS) results with p<1×10-4 . 26 
Table S13: Pseudo-R2 of all SNPs across all GWAS as calculated by the McKelvey 
and Zavoina method. ............................................................................................................. 27 
Table S14. Physicians and nurses at health care centers participating in the collection 
of FinnDiane patients. ............................................................................................................ 28 
Table S14: Members of the SUMMIT consortium. ............................................................ 32 
Figure S1. Manhattan and QQ Plots for each case-control definition and covariate 
model (minimal and full) ........................................................................................................ 42 
Figure S2. Regional chromosomal location plots and forest plots by cohort of newly 
discovered DKD associations .............................................................................................. 62 
Figure S3. Correlation of expression of COL4A3 with degree of fibrosis and eGFR in 
microdissected kidney samples. .......................................................................................... 70 
Figure S4. Genotype – phenotype associations at the lead loci when stratified by 
mean HbA1c <7.5% in the FinnDiane study. ...................................................................... 71 
Figure S5. Genotype – phenotype associations at the lead rs55703767 (COL4A3) 
locus when stratified by mean HbA1c <7.5% in up to 3226 individuals with type 2 
diabetes (T2D) from the GoDARTS. ................................................................................... 72 
GWAS of DKD Supplement 
2 
Figure S6. Fishplots comparing significance and directionality between minimal and 
fully adjusted models for each of the 10 phenotype definitions. ..................................... 73 
Figure S7: Association at previously reported loci (p<5×10-8) for renal complications in 
individuals with diabetes. ...................................................................................................... 75 
Figure S8: Forest plots of the associations at the previously reported lead loci from 
the GENIE consortium with largely overlapping studies. ................................................. 76 
Figure S9: Meta-analysis results for the loci that have previously been associated with 
DKD, or with eGFR or AER in the general population ..................................................... 77 
Figure S10. Expression of quantitative trait loci (eQTL) analysis in microdissected 
tubule samples........................................................................................................................ 79 
Figure S11. Functional annotation of TAMM41. ................................................................ 80 
Supplemental Methods: Cohort descriptions ..................................................................... 81 
References .............................................................................................................................. 88 
GWAS of DKD Supplement 
3 
 
SUPPLEMENTAL METHODS.  
Cohorts in GWAS. The GWAS meta-analysis included up to 19,406 patients with type 1 
diabetes and of European origin from 17 cohorts: The Austrian Diabetic Nephropathy Study 
(AusDiane); The Coronary Artery Calcification in Type 1 Diabetes (CACTI)1; the Diabetes 
Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications 
(DCCT/EDIC)2, 3; Pittsburgh Epidemiology of Diabetes Complications Study (EDC)4; The Finnish 
Diabetic Nephropathy (FinnDiane) Study5, 6; French and Belgian subjects from the Genetics of 
Diabetic Nephropathy (GENEDIAB)7 and Genesis8 studies; Genetics of Kidneys in Diabetes US 
Study (GoKinD) from George Washington University (GWU-GoKinD)9; patients from the Joslin 
Kidney Study9, 10; individuals with T1D from Italy5; The Latvian Diabetic Nephropathy Study 
(LatDiane)11; The Lithuanian Diabetic Nephropathy Study (LitDiane) [Reference pending, 
submitted]; The Romanian Diabetic Nephropathy Study (RomDiane)12; The Scottish Diabetes 
Research Network Type 1 Bioresource (SDRNT1BIO)13, 14; individuals with T1D from Steno 
Diabetes Center15; individuals with T1D from Uppsala, Sweden16, 17; UK GoKinD, Warren 3 and 
All Ireland (UK-ROI) study18; and The Wisconsin Epidemiologic Study of Diabetic Retinopathy 
(WESDR)19. All participants gave informed consent and all studies were approved by ethics 
committees from all participating institutions. 
 
GWAS Genotyping. Samples were genotyped on the HumanCore BeadChip (Illumina, San 
Diego, CA, USA), which contains 250,000 genome-wide tag SNPs (and other variants) and over 
200,000 exome-focused variants. All samples were passed through a stringent quality control 
protocol. Following initial genotype calling with Illumina software, all samples were re-called with 
zCall, a calling algorithm specifically designed for rare SNPs from arrays. Once calling was 
completed for all cohorts, our pipeline updated variant orientation and position aligned to hg19 
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(Genome Reference Consortium Human Build 37, GRCh37). Variant names were updated 
using 1000 Genomes as a reference. The data were then filtered for low quality variants (e.g. 
call rates <95% or excessive deviation from Hardy-Weinberg equilibrium) or samples (e.g. call 
rates <98%, gender mismatch, extreme heterozygosity). Principal Component Analysis (PCA) 
was performed separately for each cohort in order to empirically detect and exclude outliers with 
evidence of non-European ancestry. Genotypes were expanded to a total of approximately 49 
million by imputation, using 1,000 Genomes Project (phase 3 version 5) as a reference. 
 
GWAS Phenotype definitions. Participant renal status was evaluated on the basis of both 
albuminuria and eGFR. We defined a total of 10 different case-control outcomes to cover the 
different aspects of renal complications (Figure 1). Five comparisons (“All vs. ctrl”, “Micro”, 
“DN”, “Macro”, and “ESRD vs. macro”) were based on albuminuria, measured by albumin 
excretion rate (AER) from overnight or 24-h urine collection, or by albumin creatinine ratio 
(ACR). Two out of three consecutive collections were required (when available) to classify the 
renal status of subjects as either normoalbuminuria, microalbuminuria, macroalbuminuria, or 
ESRD; for detailed thresholds, see Table S9. Controls with normal AER were required to have a 
minimum diabetes duration of 15 years; subjects with microalbuminuria/ macroalbuminuria/ 
ESRD were required to have minimum diabetes duration of 5/ 10/ 10 years, respectively, in 
order to exclude renal complications of non-diabetic origins. Two comparisons (“ESRD vs. ctrl” 
and “ESRD vs. non-ESRD”) were based on presence of end-stage renal disease as defined by 
eGFR< 15 mL/min or dialysis or renal transplant. Two phenotypes (“CKD” and “CKD extreme”) 
were defined based on estimated glomerular filtration rate (eGFR; evaluated with the CKD-EPI 
formula): Controls had eGFR ≥ 60ml/min/1.73m2 for both phenotypes, and minimum of 15 years 
of diabetes duration; cases had eGFR <60ml/min/1.73m2 for the “CKD” phenotype, and eGFR 
<15 ml/min/1.73m2 or dialysis or renal transplant for the “CKD extreme” phenotype, and 
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minimum of 10 years of diabetes duration. For the “CKD-DN” phenotype that combined both 
albuminuria and eGFR data, controls were required to have both eGFR ≥60ml/min/1.73m2 and 
normoalbuminuria; cases had both eGFR <45ml/min/1.73m2 and micro- or macroalbuminuria, or 
ESRD.  
 
GWAS Statistical Analysis. A genome-wide association analysis of each of the case-control 
definitions was performed using logistic regression under an additive genetic model, adjusting 
for age, sex, diabetes duration, study site (where applicable) and principal components. As 
disease onset and progression is also closely related to BMI and HbA1c levels,20 we conducted 
a second set of analyses adjusting for BMI and HbA1c which we refer to as our fully adjusted 
covariate model. Allele dosages were used to account for imputation uncertainty. Inverse-
variance fixed effects meta-analysis was performed using METAL and the following filters: INFO 
score >0.3, minor allele count >10, and presence of variant in at least two cohorts. The X 
chromosome was similarly analyzed for males and females both separately and in a combined 
analysis, with the exception of using hard call genotypes in place of allele dosages. The study-
wide significance threshold (P<6.76×10-9) was calculated by applying a Bonferroni correction to 
the traditional GWAS threshold (P<5.00×10-8), based on the number of effectively independent 
tests, using methods previously described on the eigenvalues of the GWAS summary statistics 
correlation matrix21.  
 
Glomerular basement membrane measurement in Renin-Angiotensin System Study 
(RASS). RASS was a double-blind placebo-controlled randomized trial of the angiotensin 
converting enzyme inhibitor (ACEi) enalapril and the angiotensin II receptor blocker (ARB) 
losartan on renal pathology among 285 normoalbuminuric, normotensive subjects with T1D and 
had normal or increased measured glomerular filtration rate (>90 ml/min/1.73m2)22. Beginning in 
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2005, participants were recruited from three centers: University of Minnesota (Minneapolis, 
Minnesota), McGill University (Montreal, Canada) and University of Toronto (Toronto, Canada) 
and included those with 2 to 20 years of diabetes and excluded those on any antihypertensive 
medications. Written informed consent was obtained from each participant and the study was 
approved by the relevant institutional review boards. RASS study participants were followed for 
5 years with percutaneous kidney biopsy completed prior to randomization and at 5 years. 
Structural parameters measured by electron microscopy on biopsy included GBM width, 
measured by the electron microscopic orthogonal intercept method22. 
RASS study participants were followed for 5 years with percutaneous kidney biopsy completed 
prior to randomization and at 5 years. Structural parameters measured by electron microscopy 
on biopsy included GBM width, measured by the electron microscopic orthogonal intercept 
method22. 
RASS genotyping: All RASS participants contributed DNA for genotyping on the Illumina 
HumanOmni1-Quad and HumanCoreExome beadchip arrays. Genotypes were called using 
BeadStudio/Genomestudio software (Illumina®). Quality control (QC) measures included 
removing duplicate samples, samples with evidence of contamination (heterozygosity range 
0.25-0.32) and those with cryptic relatedness identity-by-state (IBS) (n=24). Principal 
component analyses were completed and 7 non-European outliers were removed. Of those 
genotyped, 1 participant was missing kidney biopsy data. 
RASS GBM width analysis: We completed linear regression of the COL4A3 variant 
(rs55703767) and within person mean GBM width (nm) from both baseline and 5 year 
measures, in additive and genotypic genetic models. Both univariate and multivariate analyses 
were run including sex, baseline age and diabetes duration, within person mean HbA1c over 5 
years, indicators for treatment group assignment and treatment center. A two-sided significance 
threshold of alpha <0.05 was applied. 
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In silico replication in SUMMIT consortium. The SUMMIT consortium included up to 5193 
subjects with type 2 diabetes, with and without kidney disease, of European ancestry. All 
studies were approved by ethics committees from relevant institutions and all participants gave 
informed consent23. Complete list of SUMMIT Consortium members provided in Table S13. 
SUMMIT genotyping and statistical analysis: SUMMIT Cohorts were genotyped on the 
Affymetrix SNP 6.0, the Illumina Omni express and the Illumina 610Quad arrays. QC measures 
included filtering out low frequency (<1% MAF) variants, filtering out low quality variants or 
samples, removal of duplicate samples, and removal of non-European samples based on 
principal component analysis.23 Genome-wide association analyses were performed for DKD 
trait definitions harmonized with seven of our primary T1D analyses: “DN”, “Micro”, “Macro”, 
“ESRD”, “ESRD vs. non-ESRD”, “CKD”, and “CKD-DN” under an additive model, adjusting for 
age, gender and duration of diabetes. 
 
RNA-sequencing and cis-eQTL analysis in human kidney samples from University of 
Pennsylvania cohort. Human kidney tissue collection was approved by the University of 
Pennsylvania Institutional Review Board. Kidney samples were obtained from surgical 
nephrectomies. Nephrectomies were de-identified, and the corresponding clinical information 
was collected through an honest broker; therefore, no consent was obtained from the subjects. 
Tubular and glomerular eQTL data sets were generated by 121 samples of tubules and 119 
samples of glomeruli, respectively. The cis window was defined as 1 megabase up- and down-
stream of the transcriptional start site (±1Mb). Whole kidney cis-eQTL (further just referred to as 
eQTL) data set was generated from 96 human samples were obtained from The Cancer 
Genome Atlas (TCGA) through the TCGA Data portal24.  
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RNA-sequencing of human kidney samples in the University of Pennsylvania cohort: Human 
kidney tissue was manually microdissected under a microscope in RNAlater for glomerular and 
tubular compartments. The local renal pathologist performed an unbiased review of the tissue 
section by scoring multiple parameters, and RNA were prepared using RNAeasy mini columns 
(Qiagen, Valencia, CA) according to manufacturer's instructions. RNA quality was assessed 
with the Agilent Bioanalyzer 2100 and RNA integrity number scores above 7 were used for 
cDNA production. The library was prepared in the DNA Sequencing Core at University of Texas 
Southwestern Medical Center. One microgram total RNA was used to isolate poly(A) purified 
mRNA using the Illumina TruSeq RNA Preparation Kit. We sequenced samples for single-end 
100bp, and the annotated RNA counts (fastq) were calculated by Illumina’s CASAVA 1.8.2. 
Illumina sequence quality was surveyed with FastQC. Adaptor and lower-quality bases were 
trimmed with Trim-galore. Trimmed reads were aligned to the Gencode human 
genome(GRCh37) with STAR-2.4.1d. The readcount of each sample was obtained using 
HTSeq-0.6.1 (htseq-count) and then normalized fragments per kilobase million values were 
used to perform association analysis with fibrosis and sclerosis using linear regression. 
Human kidney cis-eQTL analysis. Nominal p-values were calculated for each SNP-gene pair 
with FastQTL using linear regression with an additive effects model, and adjusted by six 
genotype PCs. 
RNA-sequencing of human kidney samples. Normalized fragment per kilobase million values 
were used to perform association analysis with fibrosis and sclerosis using linear regression. 
 
RNAseq and microarray profiling of human kidney samples from the Pima cohort. Kidney 
biopsy samples from the Pima Indian cohort were manually micro-dissected into 119 glomerular 
and 100 tubule-interstitial tissues to generate gene expression profiles25. Expression profiling in 
the Pima Indian cohort kidney biopsies was carried out using Affymetrix GeneChip Human 
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Genome U133 Array and U133Plus2 Array, as reported previously, and Affymetrix Human Gene 
ST Genechip 2.126, 27, and on RNA-seq (Illumina). The libraries were prepared using the 
ClonTech SMARTSeq v4 Ultra Low Input polyA selection kit. Samples were sequenced on a 
HiSeq 4000, single end, 75bp. Mapping to human reference genome GRCh38.7 was performed 
with STAR 2.5.2b (https://github.com/alexdobin/STAR). For annotation and quantification of 
mapping results we used cufflinks, cuffquant and cuffnorm in version 2.2.1 (https://cole-trapnell-
lab.github.io/cufflinks/). After mapping and quantification, PCA and Hierarchical Clustering was 
used to identify outliers and reiterated until no more outliers could be identified.  
eQTL analysis. Analysis was performed with Robust Multi-array Average quantile 
normalization28 after removing probes overlapping with variants identified by WGS. Batch 
effects between platforms were corrected using ComBat29 and unknown batch effects were also 
adjusted using singular value decomposition with first four eigenvectors. eQTL mapping was 
performed using EPACTS (https://genome.sph.umich.edu/wiki/EPACTS) software tool using 
linear mixed model accounting for hidden familial relatedness, after inverse Gaussian 
transformation of expression levels, adjusting for age and sex. 
 
Mouse kidney single cell RNA-sequencing. Animal studies were approved by the Institutional 
Animal Care and Use Committee of the University of Pennsylvania. We mated Cdh16Cre mice 
(Jackson Lab, 012237), Nphs2Cre mice (Jackson Lab, 008205) and SclCre mice (MGI number is 
3579158) with Tomato-GFP (mT/mG) mice (Jackson Lab, 007576) to generate 
Cdh16CremT/mG, SclCremT/mG and Nphs2cremT/mG mice30. 
Mouse kidney single cell RNA-sequencing: Kidneys were harvested from 4 to 8-week-old male 
mice with C57BL/6 background and dissociated into single cell suspension as described in our 
previous study31. The single cell sequencing libraries were sequenced on an Illumina HiSeq 
with 2x150 paired-end kit. The sequencing reads were demultiplexed, aligned to the mouse 
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genome (mm10) and processed to generate gene-cell data matrix using Cell Ranger 1.3 
(http://10xgenomics.com)31. 
To calculate the average expression level for each cluster, a z-score of normalized expression 
value was first obtained for every single cell. Then, we calculated the mean z-scores for 
individual cells in the same cluster, resulting in 16 values for each gene.  
 
Genomic features of human kidney. Human kidney-specific chromatin immunoprecipitation 
followed by sequencing (ChIP-seq) data can be found at GEO: GSM621634, GSM670025, 
GSM621648, GSM772811, GSM621651, GSM1112806, GSM621638. Different histone 
markers were combined into chromatin states using ChromHMM32. 
 
Gene and gene set analysis. PASCAL gene and pathway scores were conducted on all 20 
sets of GWAS summary statistics (10 outcomes and 2 covariate models). Gene scores were 
derived using the sum option, averaging association signal across each gene using the default 
50kb window size. Pathway scores were then computed from pathway member gene scores 
where membership was defined using default pathway libraries from BioCarta, REACTOME, 
and KEGG. Using a similar approach, MAGMA (v1.06) gene and pathway scores were 
conducted on all GWAS summary statistics using both the default gene region defined by the 
transcription start and stop sites and a 5kb window definition. MAGMA pathway analysis 
included all 1077 of the PASCAL reported libraries plus an additional 252 pathways included in 
MSigDB canonical pathway set. MAGENTA (vs2, July 2011) pathway analysis included 4725 
pathways with a minimum of five genes within the gene set. Gene sets were obtained with the 
MAGENTA distribution and included Gene ontology terms, PANTHER sets (biological 
processes, molecular functions, metabolic and signaling pathways), KEGG pathways, and 
GWAS of DKD Supplement 
11 
Ingenuity pathways. DEPICT gene set enrichment uses a more comprehensive collection of 
gene sets that allows genes to have a continuous probability for gene set membership. We 
conducted DEPICT individually on all 20 sets of GWAS summary statistics with P< 1.0 × 10-5. 
We conducted two additional pooled analyses using genome-wide minimum P-values from: 1) 
All 20 analyses (10 phenotypes and 2 covariate models) and 2) Sixteen analyses of the 8 most 
related phenotypes (8 phenotypes and 2 covariate models) which excluded ESRD vs Macro and 
Micro.  
 
Data and Software Availability  
All cohorts can share genome-wide meta-analysis summary statistics. Individual level genotype 
data: due to restrictions set by study consents and by EU and national regulations, individual 
genotype data cannot be shared for all cohorts
GWAS of DKD Supplement 
12 
Table S1. Cohorts contributing to analyses.  
This table can be found in a separate excel sheet, Supplemental_table_S1.xlsx 
 
 
 
Table S2. Characteristics of RASS participants. Categorical variables display counts and percentage. Continuous values are 
mean ± standard deviation. 
 
Variables (Total N = 253) Freq(%)/Mean±SD 
Sex - Female 134 (53%) 
Age (years) 30 ± 10 
T1D duration (years) 11 ± 5 
Within-person mean HbA1c (%)            
                                               (mmol/mol) 
8.6 ± 1.4 
70 ± 15  
Mean GBMW (nm) 480 ± 88 
rs55703767 – GG 
                       GT 
                       TT 
163 (64%) 
80 (32%) 
10 (4%) 
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Table S3. Multivariate analysis of association between rs55703767 and GBM width 
 
  Variables Adjusted model 
 
Fully adjusted model* 
Effect (SE) P 
 
Effect (SE) P 
rs55703767 (T allele)
¶
 -22.8 (8.2) 0.006 
 
-19.7 (8.2)
¶
 0.0172 
Females (vs males) -48.4 (9.3) <.0001  -50.4 (9.3) <.0001 
Age at baseline (yrs) -2.4 (0.5) <.0001  -2.4 (0.5) <.0001 
Diabetes duration (yrs) 3.8 (1.0) 0.0002  3.8 (1.0) 0.0002 
Mean HbA1c (%) 27.2 (3.3) <.0001  27.4 (3.3) <.0001 
Treatments Placebo - -  Reference  
Enalapril - -  -6.9 (11.2) 0.538 
  Losartan - -  1.4 (10.9) 0.896 
Centres Montreal - -  Reference 
  Toronto - -  0.8 (12.8) 0.952 
  Minnesota - -  18.9 (13.7) 0.169 
* Fully adjusted model also included 3 principal components for population structure within Europeans. 
¶ 
SNP genotypes modelled as additive genetic effects. 
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Table S4: Look-up of the lead loci in GWAS on eGFR in the general population (Gorski et al., 2017).33 
 
  Meta-analysis results GWAS on eGFR (Gorski 2017) 
Nearest 
Gene SNP EA NEA EAF SE OR Pmin PFull EAF β SE P N 
COL4A3 rs55703767 T G 0.206 0.03 0.79 5.34×10-12 8.19×10-11 0.142 0.002 0.0013 0.132 110517 
COL4A3 rs55703767 T G 0.209 0.04 0.79 9.28×10-9 9.38×10-9 0.142 0.002 0.0013 0.132 110517 
COL4A3 rs55703767 T G 0.205 0.03 0.84 3.88×10-10 9.68×10-9 0.142 0.002 0.0013 0.132 110517 
COL4A3 rs55703767 T G 0.208 0.04 0.77 5.30×10-9 3.77×10-8 0.142 0.002 0.0013 0.132 110517 
PRNCR1 rs551191707 CA C 0.122 0.1 1.7 4.39×10-8 3.15×10-6      
STXBP6   rs61983410 T C 0.787 0.04 1.26 9.84×10-8 3.06×10-8 0.841 -0.001 0.0012 0.336 110516 
COLEC11 rs12615970 A G 0.867 0.05 1.31 9.43×10-9 1.60×10-7      
LINC01266 rs115061173 A T 0.014 0.41 9.39 4.07×10-8 4.08×10-5      
SNCAIP rs149641852 T G 0.012 0.39 9.03 1.37×10-8 --- 0.009 0.002 0.0042 0.643 109257 
PAPLN rs113554206 A G 0.012 0.3 4.62 5.39×10-7 8.46×10-9 0.007 -0.005 0.0064 0.408 95870 
STAC  rs116216059 A C 0.016 0.38 
8.76 
1.37×10-8 
1.41×10-4 0.006 3.00×10-4 0.0043 0.953 108165 
HAND2-AS1 rs145681168 A G 0.986 0.33 0.18 2.06×10
-7 5.40×10-9 0.993 0.003 0.0067 0.612 64752 
TAMM41 rs142823282 A G 0.983 0.31 0.15 8.32×10-10 1.13×10-11      
VARS2 rs118124843 T C 0.011 0.24 3.78 4.42×10-8 3.37×10-8 0.031 0.011 0.0055 0.040 58794 
MUC7 rs191449639 A T 0.005 0.61 32.46 1.32×10-8 2.09×10-8      
MBLAC1 rs77273076 T C 0.008 0.39 9.12 1.04×10-8 2.28×10-7 0.007 0.006 0.0051 0.236 108694 
BMP7 rs144434404 T C 0.011 0.32 6.75 2.67×10-9 4.65×10-9 0.004 1.00×10-4 0.0072 0.993 91428 
PLEKHA7 rs183937294 T G 0.993 0.5 0.06 1.65×10
-8 2.10×10-6 
     
 rs185299109 T C 0.007 0.53 20.7 1.28×10-8 4.99×10-7      
EA: Effect allele. Positive odds ratio indicates that EA is associated with higher risk; positive beta indicates that EA is associated with higher 
eGFR, i.e. lower renal risk.  
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Table S5: Look-up of the lead loci in GWAS in the SUMMIT consortium (van Zuydam et al., 2018).23 
 
SNP Chr:pos EA NEA EAF Notable 
gene(s) 
Phenotype N OR 
 
P-value 
rs55703767 2:228121101 T G 0.211 COL4A3  DN 5190 0.911 0.08 
    0.213  CKD+DN 2243 0.867 0.09 
rs145681168 4:174500806 G A 0.017 HAND2-AS1 Micro 3477 1.034 0.97 
rs149641852 5:121774582 T G 0.018 SNCAIP CKD 4676 1.032 0.30 
rs118124843 6:30887465 T C 0.018 DDR1, VARS2 Micro 2439 1.137 0.63 
rs77273076 7:99728546 T C 0.014 MBLAC1  Micro 3252 0.866 0.48 
rs61983410 14:26004712 T C 0.184 STXBP6 Micro 3760 0.990 0.58 
rs144434404 20:55837263 T C 0.011 BMP7  Micro 2439 1.100 0.78 
Chr, chromosome; pos, position; EA: Effect allele; EAF, effect allele frequency; OR, odds ratio.  
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Table S6: Association at lead loci stratified by HbA1c <7.5%. 
 
          ALL HbA1c < 7.5% HbA1c >= 7.5%   
Locus SNP Pheno EA NEA N MAF P INFO N (case/ctrl) P OR (95% CI) N (case/ctrl) P OR (95% CI) P_HET 
COL4A3 rs55703767 MACROESRD G T 3611 0.19 2.16E-03 1.00 1165 (499/666) 0.659 0.95 (0.76;1.19) 2495 (884/1611) 9.55E-04 0.77 (0.66;0.9) 0.132 
COL4A3 rs55703767 MACRO G T 2803 0.19 0.06 1.00 837 (164/673) 0.663 1.08 (0.78;1.49) 2006 (373/1633) 6.63E-03 0.75 (0.61;0.92) 0.068 
COL4A3 rs55703767 ALLvCTRL G T 4271 0.19 7.04E-03 1.00 1344 (692/652) 0.870 0.98 (0.8;1.2) 2977 (1391/1586) 1.76E-03 0.81 (0.71;0.92) 0.114 
COL4A3 rs55703767 CKDDN G T 3059 0.19 1.17E-02 1.00 984 (379/605) 0.973 1 (0.78;1.28) 2102 (624/1478) 7.90E-03 0.79 (0.67;0.94) 0.136 
PRNCR1 rs551191707 ESRDvMACRO C CA 1371 0.14 2.50E-03 0.81 498 (340/158) 1.92E-02 1.71 (1.09;2.67) 885 (524/361) 4.79E-02 1.38 (1;1.91) 0.453 
STXBP6   rs61983410 MICRO T C 2976 0.23 3.75E-03 0.93 863 (195/668) 1.34E-02 0.69 (0.52;0.93) 2155 (526/1629) 0.067 0.85 (0.71;1.01) 0.248 
COLEC11 rs12615970 CKD A G 4264 0.14 3.13E-03 0.82 1432 (531/901) 0.086 0.81 (0.63;1.03) 3014 (833/2181) 1.62E-02 0.8 (0.66;0.96) 0.949 
LINC01266 rs115061173 ESRD T A 3119 0.00 1.89E-02 0.36 1012 (340/672) 0.284 2.63 (0.45;15.36) 2156 (524/1632) 0.085 5.98 (0.78;45.9) 0.550 
SNCAIP rs149641852 CKDEXTREMES G T 3907 0.01 3.04E-03 0.33 1323 (415/908) 0.559 1.53 (0.37;6.35) 2765 (559/2206) 6.27E-04 10.78 (2.76;42.09) 0.052 
PAPLN rs113554206 MACRO G A 2803 0.00 0.32 0.34 837 (164/673) 0.793 0.39 (0;417.59) 2006 (373/1633) 0.114 21.87 (0.48;999.19) 0.322 
STAC  rs116216059 ESRDvALL C A 4272 0.01 0.48 0.67 1340 (340/1000) 0.867 0.88 (0.2;3.89) 2984 (524/2460) 0.453 0.67 (0.23;1.93) 0.764 
HAND2-AS1 rs145681168 MICRO A G 2976 0.01 0.50 0.48 863 (195/668) 0.509 3.48 (0.09;141.38) 2155 (526/1629) 0.395 0.61 (0.19;1.91) 0.378 
TAMM41 rs142823282 MICRO A G 2976 0.00 0.93 0.15    2155 (526/1629) 0.886 1.19 (0.11;13.33) NA 
VARS2 rs118124843 MICRO C T 2976 0.01 0.93 1.00 863 (195/668) 0.533 0.59 (0.11;3.16) 2155 (526/1629) 0.769 1.15 (0.46;2.85) 0.492 
MUC7 rs191449639 MACROESRD T A 3611 0.00 0.09 0.28 1165 (499/666) 0.487 2.17 (0.24;19.36) 2495 (884/1611) 0.246 3.58 (0.42;30.94) 0.749 
MBLAC1 rs77273076 MICRO C T 2976 0.01 1.36E-04 0.37 863 (195/668) 3.98E-03 168.26 (5.14;5507.78) 2155 (526/1629) 1.68E-03 11.25 (2.48;50.97) 0.163 
BMP7 rs144434404 MICRO C T 2976 0.01 0.57 0.67 863 (195/668) 0.407 0.49 (0.09;2.61) 2155 (526/1629) 0.911 0.94 (0.3;2.91) 0.534 
PLEKHA7 rs183937294 MICRO T G 2976 0.00 0.22 0.26    2155 (526/1629) 0.288 3.79 (0.32;44.52) NA 
18p11.32  rs185299109 CKD C T 4264 0.00 0.68 0.32 1432 (531/901) 0.147 0.12 (0.01;2.09) 3014 (833/2181) 0.956 0.96 (0.21;4.45) 0.212 
Association stratified by HbA1c in the FinnDiane study. P-values <0.05 are given with scientific notation and bold. Lines with gray text had minor allele count 
(MAC)<10 in cases and/or controls and did not contribute to the meta-analysis. 
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Table S7. Association of rs55703767 with DN in DCCT/EDIC subgroups. 
 
Cohort Treatment Group DN % MAF Last measure Time to Event 
OR (95%CI) P value HR (95%CI) P value 
Primary Prevention 
(diabetes dur 1-5 yrs) 
Intensive 3% 0.22 2.86 (0.4-22) 0.32 0.91 (0.2-4.0) 0.90 
Conventional 10% 0.21 0.67 (0.3-1.4) 0.31 0.66 (0.32-1.33) 0.24 
Secondary Intervention 
(diabetes dur 1-15 yrs) 
Intensive 5% 0.20 0.86 (0.3-2.6) 0.79 0.65 (0.22-1.9) 0.43 
Conventional 13% 0.22 0.18 (0.1-0.5) 0.003 0.30 (0.13-0.68) 0.004 
OR=Odds Ratio for last measure, HR=Hazard Ratio for time to event phenotype 
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Table S8. Significant (P<0.05/18,222 genes tested = 2.74 × 10-6) gene level associations with diabetic kidney disease in 
MAGMA. 
 
Gene Phenotype Model Window Number of SNPs Total Sample Size MAGMA P-value PASCAL P-value 
SLC46A2 All vs. ctrl Min nowindow 66 17817 6.74 × 10-7 1.57 × 10-5 
   5kbwindow 93 17832 7.38 × 10-7  
  Full nowindow 64 16821 8.13 × 10-7 6.93 × 10-5 
   5kbwindow 90 16855 1.03 × 10-6  
SFXN4 Macro Full nowindow 69 11953 3.98 × 10-7 1.45 × 10-4 
   5kbwindow 86 11857 1.65 × 10-7  
COL20A1 Ckdextreme Min nowindow 111 11165 2.47 × 10-6 7.88 × 10-5 
   5kbwindow 137 11603 2.01 × 10-6  
  Full nowindow 110 8533 6.65 × 10-7 4.47 × 10-5 
   5kbwindow 136 9044 5.77 × 10-7  
 ESRD vs. All Min nowindow 111 12063 1.34 × 10-6 3.76 × 10-5 
   5kbwindow 137 12362 1.04 × 10-6  
  Full nowindow 110 8638 1.12 × 10-6 5.81 × 10-5 
   5kbwindow 136 9045 9.53 × 10-7  
GLT6D1 ESRD vs. Macro min 5kbwindow 96 4248 1.49 × 10-6 2.15 × 10-5 
SNX30 All vs. ctrl min 5kbwindow 434 18249 2.49 × 10-6 1.05 × 10-5 
 
Table S9. Top nominally significant gene level associations (P < 1.0 x 10-5) with diabetic kidney disease in PASCAL.  
 
Gene Phenotype Model Number of 
SNPs 
PASCAL  
P-value 
INIP All vs. ctrl Min 248 1.99 × 10-6 
  Full 248 5.54 × 10-6 
LCN9 ESRD vs. macro Min 301 5.25 × 10-6 
CBX8 DN Min 119 8.47 × 10-6 
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Table S10: Significant gene set and pathway analysis results.  Significantly enriched gene sets identified from at least one of the following 
methods: MAGENTA (FDR < 0.05, MAGMA (P<0.05 empirical permutation multiple testing correction), PASCAL (P<0.05/1,078 gene sets tested = 
4.64 × 10-5), and DEPICT (FDR < 0.01). 
Gene set Gene set database Phenotype Model Method 
negative regulators of RIG I MDA5 
signaling 
REACTOME ESRD vs. Macro Full MAGMA 
Platelet aggregation plug formation REACTOME Micro Min MAGMA 
negative regulators of RIG I MDA5 
signaling 
REACTOME ESRD vs. Macro Full PASCAL 
RIG I MDA5 mediated induction of IFN 
alpha beta pathways 
REACTOME ESRD vs. Macro Full PASCAL 
TRAF3 dependent IRF activation 
pathway 
REACTOME ESRD vs. Macro Full PASCAL 
TRAF6 mediated IRF activation REACTOME ESRD vs. Macro Full PASCAL 
Nitric Oxide Signaling in the 
Cardiovascular System 
Ingenuity ESRD vs. ctrl Min MAGENTA 
Nicotinic acetylcholine receptor signaling 
pathway 
Panther ESRD vs. non-ESRD Min MAGENTA 
ACTIVATED TLR4 SIGNALLING REACTOME All vs. ctrl Min MAGENTA 
Other lipid, fatty acid and steroid 
metabolism 
PANTHER BIOLOGICAL PROCESS CKD Min MAGENTA 
DNA degradation PANTHER BIOLOGICAL PROCESS CKD Min MAGENTA 
Tumor necrosis factor family member PANTHER MOLECULAR 
FUNCTION 
CKD-extreme Min MAGENTA 
TUFM (Tu Translation Elongation Factor, 
Mitochondrial) PPI subnetwork  
InWeb protein-protein interaction 
database 
DN Min DEPICT 
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Table S11. eQTL associations and chromatin conformation interactions for the lead SNPs.  
 
SNP Chr:pos EA NEA EAF Notable 
gene(s) 
eQTL   PC-HiC 
GENE P HIGH A Tissue Gene Score (Tissue) 
rs12615970 2:3745215 G A 0.133 COLEC11 (B); 
     
ALLC 10.42 (GM12878);  
     
ALLC (G) 
     
COLEC11, 
AC010907.2 
9.67 (GM12878);  
           
ADI1, AC142528.1 8.75 (GM12878);  
           
RP13-512J5.1 8.58 (GM12878);  
              
  
    RPS7 8.13 (GM12878);  
rs55703767 2:228121101 T G 0.206 COL4A3 (M, 
B, N) 
MFF 5.63×10-38 T blood   COL4A3, COL4A4 8.89 (GM12878);  
      
MFF 9.0×10-8 T Cells - Transformed 
fibroblasts 
 
IRS, RP11-395N3.2 9.36 (GM12878);  
            TM4SF20 2.2×10-7 T Cells - Transformed 
fibroblasts 
    
 
rs115061173 3:926345 A T 0.014 LINC01266 
(N) 
  
  
      
 
rs142823282 3:11910635 G A 0.011 TAMM41 (N, 
B) 
PPARG 4.6×10-7 G Colon - Sigmoid   TAMM41 10.65 (GM12878);  
rs116216059 3:36566312 A C 0.016 STAC (G) 
     
DCLK3 8.8 (GM12878);  
              
  
    STAC 10.87 (GM12878);  
rs191449639 4:71358776 A T 0.005 MUC7 (N)   
  
      
 
rs145681168 4:174500806 G A 0.014 HAND2-
AS1(G, B) 
  
  
    HAND2, HAND2-AS1 10.49 (GM12878);  
rs149641852 5:121774582 T G 0.012 SNCAIP (G)   
  
    SNX24 9.2 (GM12878);  
           
snoU13 8.93 (GM12878);  
           
SNCAIP, CTD-
2544H17.2 
9.69 (GM12878);  
              
  
    CTD-2280E9.1 10.81 (GM12878);  
rs118124843 6:30887465 T C 0.011 DDR1 (B);  HLA-C 1.00×10-18 C eQTLgen blood 
 
PSORS1C1 12.3 (Endothelial 
Precursors); 12.3 
(Endothelial Precursors); 
7.84 (Megacaryocytes); 
5.63 (Pancreatic islets);       
VARS2 (G) 
    
DPCR1, HCG21 11.49 (GM12878);  
      
HLA-U 3.56×10-10 T eQTLgen blood 
 
DDR1-AS1, DDR1 10.97 (GM12878);  
      
PSORS1C3 4.13×10-9 T eQTLgen blood 
 
RNU6-1133P 7.27 (Macrophages M2);  
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SNP Chr:pos EA NEA EAF Notable 
gene(s) 
eQTL   PC-HiC 
GENE P HIGH A Tissue Gene Score (Tissue) 
      
NCR3 9.35×10-6 C eQTLgen blood 
 
RN7SL175P, DDR1, 
GTF2H4, VARS2 
7.07 (Endothelial 
Precursors); 7.07 
(Endothelial Precursors); 
6.95 (Cardiomyocytes); 
6.89 (Pancreatic islets); 
5.43 (Megacaryocytes); 
5.09 (Macrophages M1);        
HCG22 1.5×10-5 T eQTLgen blood 
 
C6orf15 6.95 (Macrophages M1); 
6.95 (Macrophages M1); 
6.18 (Macrophages M0);        
VARS2 1.71×10-5 C eQTLgen blood 
   
      
GTF2H4 9.70×10-7 T Esophagus - 
Gastroesophageal 
Junction 
   
      
POU5F1 3.3×10-5 T Esophagus - 
Gastroesophageal 
Junction 
   
      
PSORS1C3 5.6×10-5 T Esophagus - 
Gastroesophageal 
Junction 
   
            C6orf48 1×10-4 C Nerve - Tibial       
rs77273076 7:99728546 T C 0.008 MBLAC1 (N, 
B) 
CNPY4 1.17×10-7 C eQTLgen blood 
 
MBLAC1, 
AC073842.19, RP11-
506M12.1 
NA (withn the same 
fragment);  
      
AP4M1 1.04×10-5 C eQTLgen blood 
 
LAMTOR4, 
GAL3ST4, GPC2, 
C7orf43, MIR4658 
14.82 (CD34); 14.82 
(CD34); 14.56 (GM12878);  
      
ZSCAN21 1.29×10-5 C eQTLgen blood 
 
LAMTOR4 14.14 (CD34); 14.14 
(CD34); 13.1 (GM12878);             
GATS, STAG3, 
PVRIG, AC005071.1 
14.11 (CD34); 14.11 
(CD34); 13.68 (GM12878);  
           
MCM7, AP4M1 14.11 (CD34); 14.11 
(CD34); 13.68 (GM12878);             
STAG3, GPC2 13.75 (CD34); 13.75 
(CD34); 13.36 (GM12878);             
MCM7, COPS6, 
MIR93, MIR106B, 
MIR25 
13.69 (CD34); 13.69 
(CD34); 13.67 (GM12878);  
           
CNPY4, TAF6 13.37 (GM12878); 13.37 
(GM12878); 13.14 (CD34);             
ZKSCAN1 13.23 (GM12878); 13.23 
(GM12878); 11.87 (CD34);             
ZSCAN21 13.14 (GM12878);  
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SNP Chr:pos EA NEA EAF Notable 
gene(s) 
eQTL   PC-HiC 
GENE P HIGH A Tissue Gene Score (Tissue) 
           
ZCWPW1, MEPCE 12.72 (GM12878); 12.72 
(GM12878); 11.48 (CD34);             
PILRA 12.65 (GM12878);  
           
TRIM4 12.64 (GM12878);  
           
ZCWPW1 12.61 (GM12878);  
           
SAP25, FBXO24, 
LRCH4, RP11-
44M6.3 
12.59 (GM12878);  
           
PILRB, PVRIG2P, 
STAG3L5P-
PVRIG2P-PILRB,  
12.38 (GM12878); 12.38 
(GM12878); 5.94 (Naive 
B); 5.02 (Total B);  
           
TSC22D4, NYAP1, 
AC092849.1, 
RN7SL161P, C7orf61 
12.21 (GM12878);  
           
RP11-758P17.2, 
PPP1R35, RP11-
758P17.3 
12.02 (GM12878); 12.02 
(GM12878); 11.55 (CD34);  
           
AZGP1, AZGP1P1 11.3 (Neutrophils); 11.3 
(Neutrophils); 6.07 
(Macrophages M2); 5.65 
(Total CD4 MF); 5.65 
(Total CD4 MF); 5.1 (Total 
CD4 Activated);             
BUD31, snoU13 11.03 (GM12878);  
           
ZNF3 10.83 (GM12878);  
           
ZCWPW1 8.39 (Naive B); 8.39 (Naive 
B); 5.52 (Total CD4 
Activated);             
PMS2P1 5.16 (Foetal Thymus);  
rs551191707 8:128100029 CA C 0.122 PRNCR1 ( N)  -NONE-             
rs183937294 11:16937846 G T 0.007 PLEKHA7 (G) -NONE- 
    
RNU6-585, PRP11-
466H18.1 
10.77 (cd34); 10.77 (cd34); 
9.2 (GM12878);  
           
AC116533.1, 
SNORD14B, 
SNORD14A, rps13 
10.19 (GM12878);  
           
PLEKHA7, 
OR7E14P 
9.49 (GM12878);  
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SNP Chr:pos EA NEA EAF Notable 
gene(s) 
eQTL   PC-HiC 
GENE P HIGH A Tissue Gene Score (Tissue) 
           
SOX6, C11orf58 9.15 (GM12878);  
           
SERGEF, RP1-
59M18.2 
7.56 (GM12878);  
           
OTOG 5.89 (Total CD8);  
                      USH1C 5.07 (Naive CD8);  
rs61983410 14:26004712 T C 0.213 STXBP6 (N) -NONE-         SNORD37 10.97 (GM12878);  
rs113554206 14:73740250 A G 0.012 PAPLN (G) -NONE- 
    
RP4-647C14.3 NA (within the same 
fragment);             
NUMB 21.42 (Endotheial 
precursors); 21.42 
(Endotheial precursors); 
17.38 (Pancreatic islets); 
12.32 (Megacaryocytes); 
11.56 (CD34); 9.65 
(Neutrophils); 9.61 (Naive 
B); 9.06 (Total B); 7.55 
(cardiomyocytes); 5.33 
(Naive CD4); 5.11 (Naive 
CD8);             
PAPLN, RNU6-419P, 
RP4-647C14.2 
13.67 (CD34); 13.67 
(CD34); 13.24 (GM12878);  
           
PAPLN 13.24 (CD34); 13.24 
(CD34); 12.47 (GM12878);             
PSEN1 12.08 (GM12878); 12.08 
(GM12878); 5.4 
(cardiomyocytes);             
HEATR4 12.05 (Endotheial 
precursors); 12.05 
(Endotheial precursors); 
10.98 (Megacaryocytes); 
10.45 (GM12878); 10.37 
(CD34); 9.92 (Neutrophils); 
8.84 (Pancreatic islets); 
7.98 (Monocytes); 7.3 
(Total B); 7.02 (Naive B); 
6.6 (cardiomyocytes); 5.81 
(Erythroblasts); 5.53 (Total 
CD4 Activated);             
RP1-240K6.3 11.84 (GM12878); 11.84 
(GM12878); 11.15 (CD34); 
7.49 (Endotheial 
precursors); 5.62 
(Pancreatic islets); 5.34 
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SNP Chr:pos EA NEA EAF Notable 
gene(s) 
eQTL   PC-HiC 
GENE P HIGH A Tissue Gene Score (Tissue) 
(Total B); 5.02 
(Megacaryocytes);  
           
DNAL1, RNU6-240P 11.07 (GM12878);  
           
PSEN1 10.96 (Endotheial 
precursors); 10.96 
(Endotheial precursors); 
10.56 (CD34);             
PNMA1 10.9 (GM12878);  
           
RP3-414A15.2 10.64 (GM12878); 10.64 
(GM12878); 7.24 
(Monocytes); 5.99 
(Neutrophils);             
ZFYVE1 10.53 (GM12878);  
           
PTGR2, Y_RNA, 
RP5-1021I20.4 
10.42 (CD34); 10.42 
(CD34); 10.16 (GM12878);  
           
RP4-693M11.3 10.33 (GM12878);  
           
RP4-687K1.2 9.96 (GM12878);  
           
HEATR4, C14orf169, 
AC005280.1 
9.52 (GM12878); 9.52 
(GM12878); 5.35 
(Pancreatic islets);             
RBM25 9.34 (GM12878);  
           
RP3-414A15.10 9.32 (GM12878);  
           
ELMSAN1 9.12 (GM12878);  
           
CCDC176 8.85 (GM12878);  
           
RBM25, RP11-
109N23.5 
8.74 (GM12878);  
           
ACOT6 8.74 (GM12878);  
           
DNAL1 8.7 (GM12878);  
                      FAM161B, RP5-
1021I20.5 
5.58 (Total CD8);  
rs185299109 18:1811108 T C 0.007   -NONE-         -NONE-   
rs144434404 20:55837263 T C 0.011 BMP7 (G, B) -NONE-         -NONE-   
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SNP Chr:pos EA NEA EAF Notable 
gene(s) 
eQTL   PC-HiC 
GENE P HIGH A Tissue Gene Score (Tissue) 
Notable Genes: based on genetic findings (G), (B), (N), (M); eQTL associations were searched from GTEX and eQTLgen (cis-eQTL) data sets. HIGH A: allele associated 
with higher gene expression levels. Promoter Capture Hi-C (PCHi-C) data: searched from www.chicp.org (date accessed: 1.12.2018; Schofield EC, Carver T, Achuthan P, 
Freire-Pritchett P, Spivakov M, Todd JA, Burren OS. CHiCP: a web-based tool for the integrative and interactive visualization of promoter capture Hi-C datasets. 
Bioinformatics. (2016) 15:32(16):2511-3), including 16 primary blood cell types and foetal thymocytes (Javierre et al.), CD34 and GM12878 cell line (Mifsud et al.), 
pancreatic isles (Miguel-Escalada et al,), and hESC derived cardiomyocytes (Choy et al.). Score: CHiCAGO score, values >5 were considered significant and listed. 
Protein coding genes are highleghted with bold typing. 
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Table S12: Transcriptome-wide association analysis (TWAS) results with p<1×10-4 
 
              Prediction performance N SNPs 
tissue GWAS phenotype GENE Z Score Effect P-value Var_G r2 P-value Q-value used in cov in model 
tub ESRD vs macro_min ACOT8 4.02 0.76 5.80E-05 0.06 0.04 2.46E-02 2.02E-02 30 30 31 
tub DN_min AKIRIN2 4.17 0.32 3.03E-05 0.09 0.05 1.30E-02 1.19E-02 36 39 42 
tub Macro_min AKIRIN2 4.36 0.42 1.32E-05 0.09 0.05 1.30E-02 1.19E-02 36 39 42 
glom Macro_min ARL17B -4.02 -0.21 5.91E-05 0.32 0.51 1.28E-19 1.77E-18 53 54 65 
tub All vs ctrl_min CALCOCO2 3.93 0.29 8.55E-05 0.06 0.10 3.23E-04 4.93E-04 37 37 40 
glom All vs ctrl_max EXOC2 4.10 0.20 4.06E-05 0.15 0.21 1.74E-07 3.79E-07 60 60 62 
glom 
ESRD vs non-
ESRD_max FAM132B -3.95 -0.52 7.73E-05 0.06 0.07 4.84E-03 3.91E-03 33 33 35 
tub CKD extreme_min FES -3.89 -0.40 9.97E-05 0.08 0.09 7.57E-04 1.05E-03 34 34 34 
tub ESRD_min FES -3.97 -0.42 7.07E-05 0.08 0.09 7.57E-04 1.05E-03 34 34 34 
tub ESRD vs non-ESRD_min FES -4.24 -0.42 2.27E-05 0.08 0.09 7.57E-04 1.05E-03 34 34 34 
glom ESRD vs macro_min GSDMB -3.96 -0.46 7.37E-05 0.11 0.07 4.54E-03 3.71E-03 35 35 35 
glom Macro_max HOXD1 4.02 0.88 5.71E-05 0.01 0.03 5.51E-02 3.10E-02 12 12 13 
glom Macro_min HOXD1 4.13 0.83 3.70E-05 0.01 0.03 5.51E-02 3.10E-02 12 12 13 
glom DN_max ITPR3 4.30 0.21 1.74E-05 0.19 0.38 1.09E-13 6.21E-13 33 33 35 
glom DN_min ITPR3 4.00 0.17 6.26E-05 0.19 0.38 1.09E-13 6.21E-13 33 33 35 
glom Macro_max ITPR3 4.31 0.25 1.62E-05 0.19 0.38 1.09E-13 6.21E-13 33 33 35 
glom Macro_min ITPR3 4.03 0.21 5.69E-05 0.19 0.38 1.09E-13 6.21E-13 33 33 35 
glom ESRD_min MORC1 3.94 0.44 8.03E-05 0.06 0.08 1.58E-03 1.47E-03 83 87 88 
glom Macro_max NLN 4.07 0.26 4.61E-05 0.21 0.15 1.09E-05 1.71E-05 85 86 110 
glom Macro_min NLN 4.53 0.27 5.99E-06 0.21 0.15 1.09E-05 1.71E-05 85 86 110 
glom All vs ctrl_max NPNT 3.90 0.37 9.51E-05 0.08 0.16 5.26E-06 8.75E-06 2 2 4 
glom ESRD_min PRC1 4.03 0.41 5.54E-05 0.09 0.11 3.23E-04 3.59E-04 33 33 34 
tub CKD-DN_min PRRC2C 3.92 0.81 8.74E-05 0.02 0.03 4.40E-02 3.27E-02 10 10 10 
tub ESRD_min PRRC2C 3.92 0.91 8.76E-05 0.02 0.03 4.40E-02 3.27E-02 10 10 10 
tub Macro_min TENM2 3.98 0.83 6.92E-05 0.02 0.11 1.59E-04 2.64E-04 23 59 60 
glom DN_min VPS33B 4.09 0.24 4.40E-05 0.15 0.37 2.23E-13 1.19E-12 24 24 26 
glom ESRD_min VPS33B 4.20 0.35 2.69E-05 0.15 0.37 2.23E-13 1.19E-12 24 24 26 
tub CKD extreme_max VPS9D1 -4.17 -0.54 3.01E-05 0.06 0.11 2.78E-04 4.30E-04 20 20 21 
Tissue: glomeruli (glom) or tubuli (tub); Z-core, Effect and P-value: MetaXcan's association results for the gene. Var_g: variance of the gene expression, calculated 
as W' * G * W (where W is the vector of SNP weights in a gene's model, W' is its transpose, and G is the covariance matrix). Prediction performance r2, P-value 
and Q-value: r2, p-value and q-value of tissue model's correlation to gene's measured transcriptome (prediction performance). N SNPs ... used: number of snps 
from GWAS that got used in MetaXcan analysis; ... in cov: number of snps in the covariance matrix; ... in model: number of snps in the model 
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Table S13: Pseudo-R2 of all SNPs across all GWAS as calculated by the McKelvey and Zavoina method.34 Total variance 
explained is the sum of pseudo-R2 across all SNPs with minor allele frequency (MAF) greater than 5% or 1%, noting that effect size and therefore 
variance explained tend to be overestimated with rare variants. Missing values indicate SNPs that did not pass our GWAS filters for those disease 
definitions as described in the methods section. 
 
Minimally Adjusted Model 
 
SNP Minor 
allele 
frequency 
DN All vs. 
ctrl 
CKD CKD-
DN 
CKD 
extreme 
ESRD 
vs. ctrl 
ESRD 
vs. 
non-
ESRD 
ESRD 
vs. 
macro 
Macro Micro 
rs61983410 0.213 0.00% 0.09% 0.01% 0.00% 0.04% 0.01% 0.04% 0.05% 0.01% 0.54% 
rs55703767 0.206 0.57% 0.33% 0.23% 0.65% 0.34% 0.55% 0.27% 0.03% 0.60% 0.11% 
rs12615970  0.133 0.16% 0.06% 0.52% 0.48% 0.41% 0.26% 0.21% 0.08% 0.05% 0.00% 
rs551191707 0.122 0.02% 0.00% 0.14% 0.33% 0.70% 0.69% 0.75% 1.76% 0.06% 0.01% 
rs142823282 0.017 0.04% 0.58% 0.01% NA NA NA NA NA 0.11% 3.50% 
rs116216059 0.016 0.00% 0.00% 0.13% 0.23% 2.96% 1.95% 4.40% NA 0.01% 0.00% 
rs145681168 0.014 0.01% 0.15% 0.00% 0.08% 0.17% NA NA NA 0.03% 2.41% 
rs115061173 0.014 0.47% 0.24% 0.34% 1.44% 2.24% 3.96% 2.57% NA 0.12% 0.01% 
rs113554206 0.012 0.97% 0.27% 0.42% NA NA NA NA NA 1.64% NA 
rs149641852 0.012 0.12% 0.02% 0.21% 2.14% 3.39% 1.94% 1.30% NA 0.07% 0.03% 
rs144434404 0.011 0.05% 0.38% 0.12% NA NA NA NA NA NA 2.43% 
rs118124843 0.011 0.06% 0.22% 0.05% 0.09% NA NA NA NA NA 1.17% 
rs77273076 0.008 0.08% 0.30% 0.09% 0.12% NA NA NA NA NA 2.28% 
rs183937294 0.007 0.09% 0.47% NA NA NA NA NA NA NA 3.49% 
rs185299109 0.007 0.08% 0.05% 3.84% NA NA NA NA NA NA NA 
rs191449639 0.005 3.46% 0.17% NA NA NA NA NA NA NA NA 
variance explained 
(MAF>5%) 
0.75% 0.48% 0.89% 1.47% 1.49% 1.50% 1.26% 1.92% 0.73% 0.65% 
variance explained 
(MAF>1%) 
2.46% 2.34% 2.17% 5.44% 10.26% 9.36% 9.53% 1.92% 2.68% 10.21% 
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Fully Adjusted Model 
 
SNP Minor 
allele 
frequency 
DN All vs. 
ctrl 
CKD CKD-
DN 
CKD 
extreme 
ESRD 
vs. ctrl 
ESRD 
vs. 
non-
ESRD 
ESRD 
vs. 
macro 
Macro Micro 
rs61983410 0.213 0.01% 0.14% 0.02% 0.01% 0.04% 0.00% 0.02% 0.01% 0.02% 0.63% 
rs55703767 0.206 0.60% 0.31% 0.25% 0.72% 0.33% 0.51% 0.27% 0.02% 0.70% 0.11% 
rs12615970  0.133 0.17% 0.07% 0.50% 0.46% 0.34% 0.22% 0.22% 0.29% 0.04% 0.00% 
rs551191707 0.122 0.01% 0.00% 0.08% 0.23% 0.41% 0.49% 0.49% 1.88% 0.07% 0.00% 
rs142823282 0.017 0.04% 0.86% 0.01% NA NA NA NA NA 0.12% 4.65% 
rs116216059 0.016 0.00% 0.00% 0.03% NA NA NA NA NA 0.00% 0.00% 
rs145681168 0.014 0.01% 0.18% 0.00% NA NA NA NA NA NA 3.33% 
rs115061173 0.014 0.61% 0.26% 0.40% 2.53% 2.11% 3.01% 1.63% NA NA 0.00% 
rs113554206 0.012 1.12% 0.26% NA NA NA NA NA NA 3.99% NA 
rs149641852 0.012 0.27% 0.04% 0.74% 2.69% NA NA NA NA 0.01% 0.05% 
rs144434404 0.011 0.03% 0.40% 0.11% NA NA NA NA NA NA 2.38% 
rs118124843 0.011 0.12% 0.34% 0.17% NA NA NA NA NA NA 1.23% 
rs77273076 0.008 NA 0.37% 0.04% NA NA NA NA NA NA 1.80% 
rs183937294 0.007 NA 0.90% NA NA NA NA NA NA NA NA 
rs185299109 0.007 NA 0.00% NA NA NA NA NA NA NA NA 
rs191449639 0.005 3.60% 0.26% NA NA NA NA NA NA NA NA 
variance explained 
(MAF>5%) 
0.78% 0.52% 0.84% 1.41% 1.12% 1.22% 1.00% 2.20% 0.83% 0.74% 
variance explained 
(MAF>1%) 
2.98% 2.86% 2.30% 6.62% 3.23% 4.23% 2.63% 2.20% 4.95% 12.38% 
 
 
Table S14. Physicians and nurses at health care centers participating in the collection of FinnDiane patients.  
 
FinnDiane Study Centers Physicians and nurses 
Anjalankoski Health Centre  S. Koivula, T. Uggeldahl 
Central Finland Central Hospital, 
Jyväskylä 
T. Forslund, A. Halonen, A. Koistinen, P. Koskiaho, M. Laukkanen, J. Saltevo, M. 
Tiihonen 
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FinnDiane Study Centers Physicians and nurses 
Central Hospital of Åland Islands, 
Mariehamn 
M. Forsen, H. Granlund, A-C. Jonsson, B. Nyroos 
Central Hospital of Kanta-Häme, 
Hämeenlinna 
P. Kinnunen, A. Orvola, T. Salonen, A. Vähänen 
Central Hospital of Länsi-Pohja, 
Kemi 
H. Laukkanen, P. Nyländen, A. Sademies 
Central Ostrabothnian Hospital 
District, Kokkola 
S. Anderson, B. Asplund, U. Byskata, P. Liedes, M. Kuusela, T. Virkkala 
City of Espoo Health Centre  
Espoonlahti A. Nikkola, E. Ritola 
Tapiola M. Niska, H. Saarinen 
Samaria E. Oukko-Ruponen, T. Virtanen 
Viherlaakso  A. Lyytinen 
City of Helsinki Health Centre  
Puistola H. Kari, T. Simonen 
Suutarila A. Kaprio, J. Kärkkäinen, B. Rantaeskola 
Töölö P. Kääriäinen, J. Haaga, A-L. Pietiläinen 
City of Hyvinkää Health Centre S. Klemetti, T. Nyandoto, E. Rontu, S. Satuli-Autere 
City of Vantaa Health Centre  
Korso  R. Toivonen, H. Virtanen 
Länsimäki R. Ahonen, M. Ivaska-Suomela, A. Jauhiainen 
Martinlaakso M. Laine, T. Pellonpää, R. Puranen 
Myyrmäki A. Airas, J. Laakso, K. Rautavaara 
Rekola  M. Erola, E. Jatkola 
Tikkurila R. Lönnblad, A. Malm, J. Mäkelä, E. Rautamo 
Heinola Health Centre P. Hentunen, J. Lagerstam 
Helsinki University Central Hospital, 
Department of Medicine, Division of 
Nephrology 
A. Ahola, J. Fagerudd, M. Feodoroff, D. Gordin, O. Heikkilä, K Hietala, L. 
Kyllönen, J. Kytö, S. Lindh, K. Pettersson-Fernholm, M. Rosengård-Bärlund, M. 
Rönnback, A. Sandelin, A-R Salonen, L. Salovaara, L. Thorn, J. Tuomikangas, T. 
Vesisenaho, J. Wadén 
Herttoniemi Hospital, Helsinki V. Sipilä 
Hospital of Lounais-Häme, Forssa T. Kalliomäki, J. Koskelainen, R. Nikkanen, N. Savolainen, H. Sulonen, E. 
Valtonen 
Iisalmi Hospital E. Toivanen 
Jokilaakso Hospital, Jämsä A. Parta, I. Pirttiniemi 
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FinnDiane Study Centers Physicians and nurses 
Jorvi Hospital, Helsinki University 
Central Hospital 
S. Aranko, S. Ervasti, R. Kauppinen-Mäkelin, A. Kuusisto, T. Leppälä, K. Nikkilä, 
L. Pekkonen 
Jyväskylä Health Centre, Kyllö K. Nuorva, M. Tiihonen 
Kainuu Central Hospital, Kajaani S. Jokelainen, P. Kemppainen, A-M. Mankinen, M. Sankari 
Kerava Health Centre H. Stuckey, P. Suominen 
Kirkkonummi Health Centre A. Lappalainen, M. Liimatainen, J. Santaholma 
Kivelä Hospital, Helsinki A. Aimolahti, E. Huovinen 
Koskela Hospital, Helsinki V. Ilkka, M. Lehtimäki 
Kotka Heath Centre E. Pälikkö-Kontinen, A. Vanhanen 
Kouvola Health Centre E. Koskinen, T. Siitonen 
Kuopio University Hospital E. Huttunen, R. Ikäheimo, P. Karhapää, P. Kekäläinen, M. Laakso, T. Lakka, E. 
Lampainen, L. Moilanen, L. Niskanen, U. Tuovinen, I. Vauhkonen, E. Voutilainen 
Kuusamo Health Centre T. Kääriäinen, E. Isopoussu 
Kuusankoski Hospital E. Kilkki, I. Koskinen, L. Riihelä 
Laakso Hospital, Helsinki T. Meriläinen, P. Poukka, R. Savolainen, N. Uhlenius 
Lahti City Hospital A. Mäkelä, M. Tanner 
Lapland Central Hospital, 
Rovaniemi 
L. Hyvärinen, S. Severinkangas, T. Tulokas 
Lappeenranta Health Centre P. Linkola, I. Pulli 
Lohja Hospital T. Granlund, M. Saari, T. Salonen 
Loimaa Health Centre  A. Mäkelä, P. Eloranta 
Länsi-Uusimaa Hospital, 
Tammisaari 
I-M. Jousmaa, J. Rinne 
Malmi Hospital, Helsinki H. Lanki, S. Moilanen, M. Tilly-Kiesi 
Mikkeli Central Hospital A. Gynther, R. Manninen, P. Nironen, M. Salminen, T. Vänttinen 
Mänttä Regional Hospital I. Pirttiniemi, A-M. Hänninen 
North Karelian Hospital, Joensuu U-M. Henttula, P. Kekäläinen, M. Pietarinen, A. Rissanen, M. Voutilainen 
Nurmijärvi Health Centre A. Burgos, K. Urtamo 
Oulankangas Hospital, Oulainen E. Jokelainen, P-L. Jylkkä, E. Kaarlela, J. Vuolaspuro 
Oulu Health Centre L. Hiltunen, R. Häkkinen, S. Keinänen-Kiukaanniemi 
Oulu University Hospital R. Ikäheimo 
Päijät-Häme Central Hospital H. Haapamäki, A. Helanterä, S. Hämäläinen, V. Ilvesmäki, H. Miettinen 
Palokka Health Centre P. Sopanen, L. Welling 
Pieksämäki Hospital V. Javtsenko, M. Tamminen 
Pietarsaari Hospital M-L. Holmbäck, B. Isomaa, L. Sarelin 
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FinnDiane Study Centers Physicians and nurses 
Pori City Hospital P. Ahonen, P. Merensalo, K. Sävelä 
Porvoo Hospital M. Kallio, B. Rask, S. Rämö 
Raahe Hospital A. Holma, M. Honkala, A. Tuomivaara, R. Vainionpää 
Rauma Hospital K. Laine, K. Saarinen, T. Salminen 
Riihimäki Hospital P. Aalto, E. Immonen, L. Juurinen 
Salo Hospital A. Alanko, J. Lapinleimu, P. Rautio, M. Virtanen 
Satakunta Central Hospital, Pori M. Asola, M. Juhola, P. Kunelius, M-L. Lahdenmäki, P. Pääkkönen, M. 
Rautavirta 
Savonlinna Central Hospital  E. Korpi-Hyövälti, T. Latvala, E. Leijala 
South Karelia Central Hospital, 
Lappeenranta 
T. Ensala, E. Hussi, R. Härkönen, U. Nyholm, J. Toivanen 
Tampere Health Centre A. Vaden, P. Alarotu, E. Kujansuu, H. Kirkkopelto-Jokinen, M. Helin, S. 
Gummerus, L. Calonius, T. Niskanen, T. Kaitala, T. Vatanen 
Tampere University Hospital I. Ala-Houhala, T. Kuningas, P. Lampinen, M. Määttä, H. Oksala, T. Oksanen, K. 
Salonen, H. Tauriainen, S. Tulokas 
Tiirismaa Health Centre, Hollola T. Kivelä, L, Petlin, L. Savolainen 
Turku Health Centre I. Hämäläinen, H. Virtamo, M. Vähätalo 
Turku University Central Hospital K. Breitholz, R. Eskola, K. Metsärinne, U. Pietilä, P. Saarinen, R. Tuominen, S. 
Äyräpää 
Vaajakoski Health Centre K. Mäkinen, P. Sopanen 
Valkeakoski Regional Hospital S. Ojanen, E. Valtonen, H. Ylönen, M. Rautiainen, T. Immonen 
Vammala Regional Hospital  I. Isomäki, R. Kroneld, M. Tapiolinna-Mäkelä 
Vaasa Central Hospital  S. Bergkulla, U. Hautamäki, V-A. Myllyniemi, I. Rusk 
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Table S14: Members of the SUMMIT consortium.   
Partner Name Position 
1 Michael Mark Coordinator, WP6 leader 
Boehringer-Ingelheim Markus Albertini Project manager 
Ingelheim, Germany Carine Boustany Chronic Kidney Disease, Head of Lab 
  Alexander Ehlgen Transmed 
  Martin Gerl Biomarker & Bioanlysis, Groupleader 
  Jochen Huber In vivo Scientist CMDR, Head of Lab 
  Corinna Schölch Biomarker & Bioanlysis, Head of Lab 
  Heike Zimdahl-Gelling Pharmacogenomics, Head of Lab 
      
2 Leif Groop Prof. Endocrinology; Coordinator Managing entity IMI-JU; PI; WP1 and WP6 leader 
Lund University Elisabet Agardh Prof. Ophthalmology 
Clinical Research Centre Emma Ahlqvist Postdoc 
Malmö, Sweden Tord Ajanki Communication strategist 
  Nibal Al Maghrabi Research nurse 
  Peter Almgren Biostatistician 
  Jan Apelqvist Diabetologist 
  Eva Bengtsson Assis. Prof. Cardiovascular research 
  Lisa Berglund Postdoc 
  Harry Björckbacka Assis. Prof. Cardiovascular research 
  Ulrika Blom-Nilsson LUDC administrator 
  Mattias Borell Website, server management 
  Agneta Burström Research nurse 
  Corrado Cilio Assoc. Prof. Cellular autoimmunity 
  Magnus Cinthio Assist. Prof. Electrical Measurements, Lund Technical University 
  Karl Dreja Nephrologist 
  Pontus Dunér Postdoc Exp. Cardiovasc. Research 
  Daniel Engelbertsen PhD student Exp. Cardiovasc. Research 
  Joao Fadista Postdoc 
  Maria Gomez Assoc. Prof. Cardiovascular disease, WP4 co-leader 
  Isabel Goncalves Assis. Prof. Cardiovascular research 
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  Bo Hedblad Prof. Cardiovascular epidemiology 
  Anna Hultgårdh Prof. Vessel Wall Biology 
  Martin E. Johansson Pathologist 
  Cecilia Kennbäck Laboratory Engineer 
  Jasmina Kravic Database manager 
  Claes Ladenvall Genetic statistician 
  Åke Lernmark Prof. Type 1 diabetes and celiac disease 
  Eero Lindholm Physician, Researcher Diabetic Complications 
  Charlotte Ling Assist. Prof. Epigenetics 
  Holger Luthman Prof. Medical genetics 
  Olle Melander Assoc. Prof. Hypertension and cardiovascular disease 
  Malin Neptin Biomedical analyst 
  Jan Nilsson Prof. Experimental Cardiovascular research, WP3 leader 
  Peter Nilsson Prof. Internal medicine 
  Tobias Nilsson PhD student Electrical Measurements, Lund Technical University 
  Gunilla Nordin Fredriksson Prof. Cardiovascular research 
  Marju Orho-Melander Prof. Genetic epidemiology 
  Emilia Ottoson-Laakso PhD student 
  Annie Persson Research nurse 
  Margaretha Persson Laboratory Engineer 
  Mats-Åke Persson Database manager 
  Jacqueline Postma Project manager 
  Elisabeth Pranter Research nurse 
  Sara Rattik PhD student Exp. Cardiovasc. Research 
  Gunnar Sterner Chief physician Internal Medicine Research Unit 
  Lilian Tindberg Research nurse 
  Maria Wigren Postdoc Exp. Cardiovasc. Research 
  Anna Zetterqvist PhD student 
  Mikael Åkerlund Postdoc 
  Gerd Östling Laboratory Engineer 
      
3 Timo Kanninen Technical director; PI 
Biocomputing Platforms  Anni Ahonen-Bishopp Software development manager 
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(BC Platforms) Anita Eliasson Financial and administrative director 
Espoo, Finland Timo Herrala System (server) specialist 
  Päivi Tikka-Kleemola Service manager 
      
4 Anders Hamsten Prof. Cardiovascular disease; Atherosclerosis Research Unit; PI 
Karolinska Institute Christer Betsholtz Prof. Vascular biology 
Stockholm, Sweden Ami Björkholm Administrator 
  Ulf de Faire Professor emeritus Cardiovascular epidemiology 
  Fariba Foroogh Research engineer 
  Guillem Genové Scientist 
  Karl Gertow Research Assist. Prof. Cardiovascular genetics 
  Bruna Gigante Assoc. Professor Cardiovascular epidemiology 
  Bing He Postdoc 
  Karin Leander Assoc. Professor Cardiovascular epidemiology 
  Olga McLeod Postdoc 
  Maria Nastase-Mannila Postdoc 
  Jaako Patrakka Postdoc 
  Angela Silveira Assoc. Prof. Cardiovascular genetics 
  Rona Strawbridge Postdoc 
  Karl Tryggvason Prof. Medical Chemistry 
  Max Vikström Statistician 
  John Öhrvik Professor 
  Anne-May Österholm  Postdoc 
      
5 Barbara Thorand Nutritional scientist, epidemiologist 
Helmholtz Centre Christian Gieger Statistician 
Munich, Germany Harald Grallert Biologist 
  Tonia Ludwig Statistician 
  Barbara Nitz Scientist 
  Andrea Schneider Data manager 
  Rui Wang-Sattler Scientist 
  Astrid Zierer Statistician 
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6 Giuseppe Remuzzi Institute director; PI 
Mario Negri Institute for  Ariela Benigni Head of department Molecular Medicine 
Pharmacological Research Roberta Donadelli Scientist 
  Maria Domenica Lesti Researcher 
Bergamo, Italy Marina Noris Head Laboratory Immunology and genetics of transplantation and rare diseases 
  Norberto Perico Senior scientist 
  Annalisa Perna Biostatistician 
  Rossella Piras Postdoc 
  Piero Ruggenenti Head of department Renal medicine, Assist. Prof. Nephrology and dialysis 
  Erica Rurali Postdoc 
      
7 
David Dunger (att: Jane 
Horsford) Prof. Paediatrics; PI 
University of Cambridge Ludo Chassin Senior Data Manager 
UK Neil Dalton, London Clinical biochemistry 
  John Deanfield, London Paediatric cardiology 
  Jane Horsford PA to Prof. Dunger 
  Clare Rice Operations manager/financial contact 
  James Rudd Cardiovascular imaging 
  Neil Walker Head Data services 
  Karen Whitehead Technician 
  Max Wong Postdoc 
      
8 Helen Colhoun Prof. Public health and epidemiology; PI; Vice coordinator Managing entity; WP2 leader 
  Fiona Adams   
University of Dundee Tahira Akbar PA to Helen Colhoun 
Scotland Jill Belch Prof. Vasucular disease 
  Harshal Deshmukh PhD student 
  Fiona Dove   
  Angela Ellingford NHS Tayside Diabetic Retinopathy Screening Programme manager 
  Bassam Farran Statistician 
  Mike Ferguson Dean of research Biological chemistry and drug discovery 
  Gary Henderson   
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  Graeme Houston Consultant radiologist/senior lecturer 
  Faisel Khan Reader, Vascular & Inflammatory Diseases Research Unit 
  Graham Leese Consultant diabetologist/reader 
  Yiyuan Liu PhD student 
  Shona Livingstone Senior statistician 
  Helen Looker Epidemiologist 
  Margaret McCann Project assistant  
  Stuart McGurnaghan Lead data programmer 
  Andrew Morris Prof. Diabetic medicine 
  David Newton   
  Colin Palmer Prof. Pharmacogenomics 
  Ewan Pearson Consultant diabetologist/senior lecturer 
  Gillian Reekie Research Nurse 
  Natalie Smith Research Nurse 
      
9 Angela Shore Prof. Cardiovascular Science, PI 
Peninsula Medical School Kuni Aizawa Postdoc 
Exeter, UK Claire Ball Research nurse 
  Nick Bellenger Cardiologist 
  Francesco Casanova Associate Research Fellow Vascular medicine 
  Tim Frayling Prof. Genetics 
  Phil Gates Senior lecturer Cardiovascular science 
  Kim Gooding Postdoc Vascular medicine 
  Andrew Hatttersley Prof. Molecular medicine 
  Roland Ling Consultant opthalmologist 
  David Mawson Research technician 
  Robin Shandas Prof. Bioengineering (Colorado) 
  David Strain Stroke physician, clinical lecturer 
  Clare Thorn Postdoc Vascular medicine 
      
10 Ulf Smith Prof. ; PI 
University of Gothenburg Ann Hammarstedt Researcher Molecular and clinical medicine 
Sweden Hans Häring Prof. University of Tübingen 
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  Oluf Pedersen Prof. Steno Centre, Copenhagen 
  Georgio Sesti Prof. Universtiy of Catanzaro 
      
11 Per-Henrik Groop Prof. Diabetes genetics; PI 
  Emma Fagerholm MSc; PhD student, genetics 
Folkhälsan Carol Forsblom Clinical coordinator 
Helsinki, Finland Valma Harjutsalo PhD; FinnDiane Co-PI 
  Maikki Parkkonen Laboratory manager 
  Niina Sandholm DSc(PhD); GWAS and bioinformatics, FinnDiane Co-PI 
  Nina Tolonen MD PhD 
  Iiro Toppila BSc, MSc; bioinformatician 
  Erkka Valo MSc; PhD student, bioinformatician 
      
12 Veikko Salomaa Prof. Epidemiology; PI; deputy leader WP2 
The National Institute for 
Health and Welfare Aki Havulinna DSc. (tech), statistician 
Helsinki, Finland Kati Kristiansson PhD 
  Pia Okamo THL press officer 
  Tomi Peltola PhD 
  Markus Perola Professor 
  Arto Pietilä Statistician 
  Samuli Ripatti Professor, Statistics 
  Marketta Taimi Research assistant 
      
13 Seppo Ylä-Herttuala Prof.; PI; WP4 leader 
University of Eastern 
Finland Mohan Babu PhD student 
Kuopio, Finland Marike Dijkstra PhD student 
  Erika Gurzeler PhD student 
  Jenni Huusko PhD student 
  Ivana Kholová Postdoc 
  Markku Laakso Prof.  
  Mari Merentie PhD student 
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  Marja Poikolainen PA Prof Ylä-Herttuala 
      
14 Mark McCarthy 
Prof. Human type 2 diabetes; Oxford Centre for Diabetes, Endocrinology and Metabolism; 
Wellcome Trust Centre for Human Genetics; PI; deputy leader WP1 
University of Oxford Will Rayner Database manager 
UK Neil Robertson Informatics 
  Natalie van Zuydam Postdoc 
      
15 Claudio Cobelli Prof. ; PI; WP5 leader 
University of Padova Barbara Di Camillo Assist. Prof.  
Italy Francesca Finotello PhD student 
 Francesco Sambo Postdoctoral fellow 
 Gianna Toffolo Prof.  
 Emanuele Trifoglio PhD student 
   
16 Riccardo Bellazzi Prof. Bioengineering; PI; deputy leader WP5 
  Nicola Barbarini Postdoctoral fellow 
University of Pavia Mauro Bucalo Software engineer 
Italy Christiana Larizza Assist. Prof.  
  Paolo Magni Assoc. Prof. 
  Alberto Malovini Postdoctoral fellow 
  Simone Marini Postdoctoral fellow 
  Francesca Mulas Postdoctoral fellow 
  Silvana Quaglini Prof. 
  Lucia Sacchi Assist. Prof.  
  Francesca Vitali   
      
17 Ele Ferrannini Prof. Medicine; PI 
  Beatrice Boldrini Postdoctoral fellow 
University of Pisa Michaela Kozakova Senior investigator Medical Pathophysiology 
Italy Andrea Mari  Senior researcher Biomedical engineering (ISIB-CNR, Padova) 
  Carmela Morizzo Biologist, Sonographer Cardiovascular ultrasound 
  Lucrecia Mota EGIR administrative office 
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  Andrea Natali Assoc. Prof. Medicine 
  Carlo Palombo Assoc. Prof. Medicine; deputy leader WP3 
  Elena Venturi Researcher 
  Mark Walker  Prof. Molecular diabetic medicine (Univ Newcastle-upon-Tyne ) 
      
18 Carlo Patrono Prof.Pharmacology; PI 
Catholic University of Rome Francesca Pagliaccia PhD student 
Italy Bianca Rocca Assist. Prof. Pharmacology 
      
19 Pirjo Nuutila Prof. ; PI 
University of Turku Johanna Haukkala PhD student 
Finland Juhani Knuuti Prof. ; Director Turku PET Centre 
  Anne Roivainen Prof. 
  Antti Saraste Adj. Prof.  
      
20 Paul McKeague Prof. Genetic Epidemiology; PI 
University of Edinburgh Norma Brown Research administrator, Public Health Services 
Scotland Marco Colombo Bioinformaticist 
      
21 Birgit Steckel-Hamann Deputy coordinator; PI, Manager IMI, LRL 
Eli Lilly Krister Bokvist Biostatistician 
  Sudha Shankar Diabetologist 
  Melissa Thomas Translational Science 
      
22 Li-ming Gan Prof.; Translational Science Director Cardiovascular Disease; PI, WP3 leader 
AstraZeneca Suvi Heinonen  PhD, Internal AZ postdoc, Bioscience 
  Ann-Cathrine Jönsson-Rylander PhD, Assoc. Prof., Team Leader Bioscience, WP4 leader 
  Remi Momo Postdoctoral fellow 
  Volker Schnecke Informatician Translational Science, WP5 leader 
  Robert Unwin Translational Science Director Diabetic Nephropathy 
  Anna Walentinsson Geneticist Translational Science 
  Carl Whatling Bioscientist 
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23 Everson Nogoceke Pre-clinical and clinical aspects of metabolic and vascular disease; PI;  WP2 leader 
Roche Gonzalo Durán Pacheco Senior Research Statistician 
  Ivan Formentini Biomarker & Experimental Medicine Leader  
  Thomas Schindler Pre-clinical and clinical and clinical biomarkers  
      
24 Piero Tortoli  Professor of Electronics 
University of Florence Luca Bassi Postdoctoral fellow 
  Enrico Boni Postdoctoral fellow 
  Alessandro Dallai Postdoctoral fellow 
  Francesco Guidi Technician 
  Matteo Lenge PhD student 
  Riccardo Matera PhD student 
  Alessandro Ramalli PhD student 
  Stefano Ricci Assist. Prof.  
  Jacopo Viti PhD student 
      
25 Bernd Jablonka SAD internal IMI coordinator 
Sanofi-aventis Dan Crowther Biomarker researcher 
  Johan Gassenhuber Biostatistician 
  Sibylle Hess Biomarker researcher 
  Thomas Hübschle Pharmacologist Diabetes 
  Hans-Paul Juretschke Imaging 
  Hartmut Rütten Head Translational Medicine 
  Thorsten Sadowski Pharmacologist Diabetes 
  Paulus Wohlfart Pharmacologist Diabetes 
     
26 Julia Brosnan Biochemist, (pre)clinical research CVD, Pfizer US; WP2 leader 
Pfizer Valerie Clerin Cardio-renal biologist, WP2 
  Eric Fauman Computational biologist 
  Craig Hyde Statistician 
  Anders Malarstig Human genetics, Pfizer Europé; WP1 leader 
  Nick Pullen Renal Disease Research Director 
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  Mera Tilley   
  Theresa Tuthill Imaging specialist 
  Ciara Vangjeli Cardiovascular genetic epidemiologist, Pfizer Europe 
  Daniel Ziemek Computational biologist 
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Figure S1. Manhattan and QQ Plots for each case-control definition and covariate model (minimal and full) 
 
DN - minimal λ = 1.011 
GWAS of DKD Supplement 
43 
 
DN - full λ = 1.009 
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macro - min λ = 1.010 
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macro - full λ = 1.012 
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ESRD vs. ctrl- min λ = 1.025 
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ESRD vs. ctrl - full λ = 1.019 
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ESRD vs. non-ESRD - 
min 
λ = 1.032 
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λ = 1.021 ESRD vs. non-ESRD - 
full 
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λ = 1.001 ESRD vs. macro - min 
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ESRD vs. macro - full λ = 1.014 
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All vs. ctrl - min λ = 1.019 
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All vs. ctrl - full λ = 1.013 
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Micro - min λ = 1.017 
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Micro - full λ = 1.010 
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CKD - min λ = 1.019 
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CKD - full λ = 1.017 
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CKD extreme - min λ = 1.027 
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CKD extreme - full λ = 1.023 
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CKD-DN - min λ = 1.018 
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CKD-DN - full λ = 1.017 
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Figure S2. Regional chromosomal location plots and forest plots by cohort of newly discovered DKD associations
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chr2:3745215 – rs12615970 – COLEC11 – CKD min 
chr3:926345 – rs115061173 – LINC01266 – ESRD vs ctrl min    
rs12615970 – CKD min 
rs115061173 – ESRD vs. ctrl min 
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chr2:228121101 – rs55703767 – COL4A3 – DN min 
chr3:11910635 – rs142823282 – TAMM41 – Micro full 
rs55703767 – DN min 
rs142823282 – Micro full 
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chr4:71358776 – rs191449639 – MUC7 – DN min 
chr5:121774582 – rs149641852 – SNCAIP – CKD extreme min 
rs191449639 – DN min 
rs149641852 – CKD extreme min 
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chr6:30865279 – rs118124843 – DDR1 – Micro full 
chr8:128100029 – rs551191707 – PRNCR1 – ESRD vs macro min 
rs118124843 – Micro full 
rs551191707 – ESRD vs. macro min 
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chr7:99728546 – rs77273076 – MBLAC1 – Micro min 
chr11:16937846 – rs183937294 – PLEKHA7 – Micro min 
rs77273076 – Micro full 
rs183937294 – Micro min 
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chr14:26004712 – rs61983410 – STXBP6 – Micro full 
chr18:1811108 – rs185299109 – 18p11 – CKD min 
rs61983410 – Micro full 
rs185299109 – CKD full 
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  chr14:73740250 – rs113554206 – PAPLN – Macro full 
chr20:55837263 – rs144434404 – BMP7 – Micro min 
rs144434404 – Micro min 
rs113554206 – Macro full 
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Figure S3. Correlation of expression of COL4A3 with degree of fibrosis and eGFR in microdissected kidney samples.  
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Figure S4. Genotype – phenotype associations at the lead loci when stratified by mean HbA1c <7.5% in the FinnDiane study. 
Only loci with a minor allele count ≥10 in each stratum are shown.  
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Figure S5. Genotype – phenotype associations at the lead rs55703767 (COL4A3) 
locus when stratified by mean HbA1c <7.5% in up to 3226 individuals with type 2 
diabetes (T2D) from the GoDARTS.   
 
For All vs. ctrl phenotype, 1632 individuals (848 cases, 784 controls) had HbA1c<7.5%, and 
1572 individuals (874 cases, 698 controls) had HbA1c>=7.5%. 
 
 
 
  
GWAS of DKD Supplement 
73 
Figure S6. Fishplots comparing significance and directionality between minimal and fully adjusted models for each of the 10 
phenotype definitions. Fishplots comparing the significance and directionality between the minimal and fully adjusted models for each of the 10 
phenotype definitions. P-values are signed according to consistency in the direction of effect between the two GWAS under comparison, such that 
the –log(P) of SNPs with effect sizes in the same direction are plotted on quadrant 1 (the head and body of the fish), and the –log(P) of SNPs with 
effect sizes in opposite directions are plotted in quadrant 3 (the tail of the fish). 
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DN macro ESRD vs. ctrl 
ESRD vs. non-ESRD ESRD vs. macro 
micro 
All vs. ctrl 
CKD CKD-DN CKD extreme 
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Figure S7: Association at previously reported loci (p<5×10-8) for renal complications in individuals with diabetes. AFF3 and 
RGMA-MCTP2 were originally reported for ESRD (T1D) (Sandholm et al., 2012); CDCA7/SP3 for ESRD in women (T1D) (Sandholm et al., 2013); 
ERBB4 for DN (T1D) (Sandholm et al., 2012); GABRR1 for microalbuminuria (T2D)(Van Zuydam et al., 2018); GLRA3 for albuminuria (T1D) 
(Sandholm et al., 2014); PRKAG2 and UMOD for eGFR (Pattaro et al., 2016; Van Zuydam et al., 2018); and SCAF8/CNKSR3 for DN (T2D) 
(Iyengar et al., 2015). 
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Figure S8: Forest plots of the associations at the previously reported lead loci from the GENIE consortium with largely 
overlapping studies. A: RGMA-MCTP2 rs12437854. B: AFF3 rs7583877. C: ERBB4 rs7588550. Meta-analysis results for RGMA-MCTP2: 
Previous P = 2.0×10-9, OR = 1.80 (95% confidence interval 1.48, 2.17), Current P = 7.4×10-4, OR = 1.31 (1.12, 1.54); Meta-analysis results for 
AFF3: Previous p=1.20×10-8, OR = 1.29 (1.18, 1.40), Current p=5.97x10-4, OR=1.15 (1.06, 1.24). Meta-analysis results for ERBB4: Previous P = 
2.1×10-7, OR = 0.66 (0.56, 0.77), Current P = 3.5×10-5, OR = 0.76 (0.67, 0.87). 
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Figure S9: Meta-analysis results for the loci that have previously been associated with DKD, or with eGFR or AER in the 
general population. Figure shows OR [95% CI] for the 25 loci with p<0.05 for at least one sub-phenotype; associations with p<0.05 are indicated 
with black confidence intervals. Results are plotted so that odds ratio (OR)>1 indicates association in the same direction with the original report (for 
eGFR, this means that the allele associated with higher risk of DN is associated with lower eGFR). A total of 69 loci were evaluated, including loci 
for DKD (5 loci: AFF3, RGMA-MCTP2, ERBB4 (Sandholm 2012), CDCA7/SP3 (Sandholm2014), SCAF8/CNKSR3 (Iyengar 2015)), for albuminuria 
in individuals with diabetes (GLRA3 (Sandholm 2013), 3 suggestive loci CUBN, HST6ST1 and RAB38 (Teumer 2016)), for eGFR in individuals with 
diabetes (UMOD, Pattaro et al. 2016 and Van Zuydam et al. 2018, PRKAG2 Van Zuydam et al. 2018) or without diabetes (61 loci, Gorski 2017). 
Associations at AFF3, RGMA-MCTP2, ERBB4, SCAF8/CNKSR3, and UMOD remained significant after correction for 69 tested loci (p<7×10-4). 
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Figure S10. Expression of quantitative trait loci (eQTL) analysis in microdissected 
tubule samples. Boxplots showing normalized gene expression by stratified by homozygous 
common (red), heterozygous (green), and homozygous rare (blue) genotype. We identified 
nominal associations for rs55703767 in tubule samples with IRS1 (a) and in glomerular samples 
with RP11-395N3.2 and AGFG1 (b). We also found nominal associations of rs61983410 with 
the gene encoding Cathepsin G, CTSG, in both eQTL analysis of whole kidney samples (c) and 
microdissected tubule samples (d). 
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Figure S11. Functional annotation of TAMM41. ChIP-seq data derived from healthy adult 
human kidney samples (Bernstein et al., 2010) shows that variants associated with 
microalbuminuria are located close to H3K27ac, H3K9ac, H3K4me1, and H3K4me3 signals, 
suggesting that this locus is an active regulator of TAMM41.
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Supplemental Methods: Cohort descriptions 
 
CACTI: The Coronary Artery Calcification in Type 1 Diabetes (CACTI) study enrolled 
656 subjects with diabetes diagnosed before age 30 years, treated with insulin within 1 
year of diagnosis, and diabetes duration of at least 10 years on enrollment.1 
DCCT/EDIC: The Diabetes Control and Complications Trial (DCCT) was a multi-center 
randomized clinical trial to compare intensive and conventional insulin therapy on the 
development and progression of early vascular and neurological complications of type 1 
diabetes (T1D). Renal outcomes were defined as time in years from DCCT baseline 
until the event. AERs were measured annually in DCCT and every other year in the 
post-study Epidemiology of Diabetes Interventions and Complications (EDIC) cohort. 
Persistent microalbuminuria was defined as the time to two consecutive AER >30 mg/24 
hours (>20.8 µg/min); severe nephropathy was the time to AER >300 mg/24 hours 
(>208 µg/min) with prior persistent microalbuminuria, or ESRD. 22% developed 
persistent microalbuminuria during follow-up (268 events, 976 censored), while 10% 
developed severe nephropathy (132 events, 1,172 censored).2, 35 
EDC: The Pittsburgh Epidemiology of Diabetes Complications (EDC) is a historical 
cohort study based on incident cases of childhood onset (prior to age 17 years) T1D, 
diagnosed or seen within one year of diagnosis (1950-80) at Children’s Hospital of 
Pittsburgh.4 The cohort, which has been shown to be epidemiologically representative 
of the Allegheny County, Pennsylvania, T1D population,36 was first assessed for the 
EDC study between 1986 and 1988 (mean participant age and diabetes duration were 
28 and 19 years, respectively). Subsequently, biennial examinations were conducted for 
10 years, with a further detailed examination at 18 and 25 years from enrollment. All 
EDC study participants provided informed consent, and all study procedures were 
approved by the University of Pittsburgh Institutional Review Board (IRB). 
Microalbuminuria was defined as albumin excretion rate (AER) 20-200 μg/min (30-300 
mg/24 hours), overt nephropathy as AER >200 μg/min (>300 mg/24 hours) and 
albuminuria as >20 μg/min (>30 mg/24 hours) in at least two of three validated timed 
urine collections. End-stage renal disease was defined as receiving dialysis or renal 
transplantation.  
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FinnDiane: Finnish Diabetic Nephropathy Study (FinnDiane) is an ongoing 
nationwide Finnish multicenter study of adult participants with T1D described previously.5, 
6 The participants were invited to the study by their attending physician who filled a 
questionnaire on the medical status of the patient and performed a clinical examination. 
A subset of the patients participated at one or more follow-up visits with a similar setting. 
Additional health related information was obtained from Finnish hospital discharge 
registry and from the patients’ medical records. Further patients were included to the 
FinnDiane study through collaboration with the Finnish National Institute for Health and 
Welfare; for these participants, health related data was obtained from the hospital 
discharge registry and from the medical records. For this study, participants were limited 
to those with T1D diagnosed prior to age 40 years and with insulin treatment begun within 
2 calendar years from diabetes onset. Disease status was defined by urine albumin 
excretion rate (AER) or urine albumin to creatinine ratio (ACR) in at least two out of three 
consecutive urine collections at local centers: microalbuminuria was defined as AER 20-
200 µg/min or 30-300 mg/24h or an ACR of 2.5-25 mg/mmol for men and 3.5-35 mg/mmol 
for women in overnight, 24-hour or spot urine collections, respectively. Similarly, the limit 
for macroalbuminuria was AER >200 µg/min or >300 mg/24h or ACR > 25 mg/mmol for 
men and >35 mg/mmol for women. ESRD was defined as ongoing dialysis treatment or 
receipt of transplanted kidney. Control patients with normal AER were required to have 
T1D duration of at least 15 years.5, 6 
France-Belgium: The GENEDIAB ('Génétique de la Néphropathie Diabétique, Genetics 
of Diabetic Nephropathy) and Genesis subjects were recruited in France, and in France-
Belgium, respectively. Patients with T1D were selected on the following criteria: 1) age at 
diabetes onset before age 35 years, and 2) definitive insulin use within one year after 
diagnosis. Diabetic nephropathy was classified according to the highest three AER 
measurements within the last 5 years. Categories included: 1) controls 
(normoalbuminuria), 2) incipient nephropathy (microalbuminuria), 3) established 
nephropathy (proteinuria), and 4) advanced nephropathy (serum creatinine >150 mol/L 
and/or renal replacement therapy).7, 8 
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GoKinD US: Genetics of Kidneys in Diabetes US Study (GoKinD): The GoKinD study 
consists of a DKD case-control cohort of individuals diagnosed with T1D prior to 31 years 
of age who began insulin treatment within 1 year of T1D diagnosis. Controls were 18-59 
years of age, with T1D for at least 15 years but without DKD. DKD definition includes 
individuals with end-state renal disease (ESRD), dialysis or kidney transplant and 
persistent macroalbuminuria (at least 2 out of 3 tests positive for albuminuria by dipstick 
≥1+, or ACR >300 µg albumin/mg of urine creatinine). Cases were defined as people 18-
54 years of age, with T1D for at least 10 years and DKD. Individuals were recruited at two 
study centers, George Washington University and the Joslin Diabetes Center using 
differing methods.9 The Joslin GoKinD subjects were analyzed jointly with subjects from 
the Joslin Microalbuminuria and 50-years medalists (see below).  
The InterDiane Consortium: The International Diabetic Nephropathy Consortium 
(InterDiane) was initiated in 2010 based on the protocol of the FinnDiane Study. The aim 
of the study is to identify risk factors for diabetic nephropathy and other chronic 
complications in patients with T1D. The participating studies follow the main protocol of 
the FinnDiane Study and use the same standardized questionnaires for data 
acquisition. T1D was defined as diabetes onset <40 years with insulin treatment initiated 
within one year of diagnosis. The main renal phenotype information has been collected 
at a baseline visit but in some countries prospective patient visits have been performed 
and additional phenotype information has been gathered. The last available phenotype 
information has been used in the analyses. Patients included fulfil the harmonized case 
and control criteria of the present study. InterDiane centers included in this study come 
from Romania, Austria, Latvia and Lithuania.  
- AusDiane: The Austrian Diabetic Nephropathy Study (AusDiane) was initiated 
in 2012 in the state of Salzburg in Austria, and is part of the InterDiane Consortium 
(please see also the InterDiane cohort description). The patients have been 
studied during a regular visit at two hospitals (Department of Internal Medicine 1, 
Paracelsus Medical University Hospital Salzburg and Diakonissen-Wehrle 
Hospital Salzburg). Recruitment was done consecutively in the outpatient 
departments of these two hospitals. Clinical data were collected mainly as part of 
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the Type 1 diabetes Registry of the state of Salzburg. Patients have been studied 
repeatedly every 1 to 1.5 years to improve the phenotype. The last available 
phenotype is used for the analysis. This study comprises 71 patients with normal 
AER and diabetes duration ≥15 years, 13 with microalbuminuria, 4 with 
macroalbuminuria and 2 with ESRD and with GWAS data available and passing 
the inclusion criteria. Renal status was assessed by morning urine samples at least 
once every year. The study received ethical approval from the local ethics 
committee (Ethikkommission Salzburg). Written consent was obtained prior to 
participation in the study. 
- The Latvian Diabetic Nephropathy Study (LatDiane) was initiated in 2012 and 
is part of the InterDiane Consortium (please see also the InterDiane cohort 
description). Recruitment of patients took place in Pauls Stradins University 
Hospital (Riga). The patients were recruited from the Endocrinology department of 
Pauls Stradins University Hospital and from out-patient clinics of Riga and Riga 
district (cities Jelgava, Jurmala, Ogre, Salaspils ect). The study comprises 80 
patients with normal AER and diabetes duration ≥15 years, 33 with 
microalbuminuria, 18 with macroalbuminuria and 7 with ESRD and with GWAS 
data available and passing the inclusion criteria. Patients from out-patients clinics 
of Riga and Riga district were invited for a separate recruitment visit following the 
invitation of their endocrinologist. Patients undergoing treatment or correction of 
therapy in Endocrinology department of Pauls Stradins University Hospital were 
recruited in the department. Renal status was assessed based on available data 
of albuminuria (albumin content in 24-hour urine or albumin/creatinine in morning 
spot urine). In addition, during the recruitment visit, morning spot urine was 
collected from all patients, and sent for albumin/creatinine measurement. For 
patients without available data on measurements of albuminuria before 
recruitment to the LatDiane Study, albumin/creatinine determination in morning 
spot urine was repeated also several weeks after recruitment. Follow-up visits are 
planned for 2018. The study received ethical approval from the Latvian Central 
Ethics Committee. Written consent was obtained prior to participation in the 
study.11 
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- The Lithuanian Diabetic Nephropathy Study (LitDiane) was initiated in 2013 
and is part of the InterDiane Consortium (please see also the InterDiane cohort 
description). Patients with T1D have been collected in a single center at the 
Hospital of Lithuanian University of Health Sciences (HLUHS) in Kaunas. Patients 
were included in the study from out-patient and inpatient departments of 
Endocrinology clinic of HLUHS during separate study visit. Medical records were 
reviewed for each patient and prospective visits are performed once a year. Renal 
status was classified based on the urinary albumin excretion rate (AER) in at least 
two out of three consecutive urine collections as: normal AER (<30mg/24h in a 24-
hour urine collection), incipient diabetic nephropathy (microalbuminuria; AER ≥30 
and <300mg/24h) or overt diabetic nephropathy (macroalbuminuria; AER 
≥300mg/24h). Patients on dialysis or with a kidney transplant were considered to 
have end-stage renal disease (ESRD). As a measure of renal function estimated 
GFR (eGFR) was calculated with the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formula. At the time of analysis, the study comprised 39 
patients with normal AER, 32 with microalbuminuria, 9 with macroalbuminuria and 
10 with ESRD and with GWAS data available and passing the inclusion criteria. 
The study received ethical approval from the Kaunas Regional Biomedical 
Research Ethics Committee (No. BE-2-16, 13-March-2013). Written consent was 
obtained prior to participation in the study.  
- The Romanian Diabetic Nephropathy Study (RomDiane) was initiated in 2010 
in Romania as the pilot study of the InterDiane Consortium. Patients have been 
studied in a cross-sectional manner in two centers in Bucharest and one in Craiova 
between 2010 and 2012. Renal status was assessed based on the AER or ACR 
in two out of three consecutive urine collections at local centers. This study 
comprises 89 patients with normal AER and diabetes duration ≥15 years, 48 with 
microalbuminuria, 70 with macroalbuminuria and 28 with ESRD, and with GWAS 
data available and passing the inclusion criteria. The study received ethical 
approval from the local ethics committee. Written consent was obtained prior to 
participation in the study.12  
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Italy: Subjects with T1D were recruited at the Complications of Diabetes Unit of the San 
Raffaele Scientific Institute, Milan, Italy. Diabetic nephropathy was defined as a median 
AER >200 µg min-1 in three overnight collections of sterile urine in patients with T1D for 
at least 10 years, concomitant diabetic retinopathy and absence of clinical or laboratory 
evidence of cardiac failure or other renal or urinary tract disease. Patients without 
nephropathy had a median AER <20 µg/min.5 
Joslin Cohort: There were 2,271 Joslin patients with T1D included in this study. These 
patients were derived from three cohorts included in the ongoing Joslin Kidney Study.10 
Recruitment of 1,600 patients into the 1st Joslin Kidney Study on Natural History of 
Microalbuminuria in T1D took place between 1991 and 1993, and the cohort was followed 
through 2004. Recruitment of 1,108 patients into the 2nd Joslin Kidney Study on Natural 
History of Early Renal Decline in T1D took place between 2003 and 2012 and the follow-
up of this cohort is still ongoing. The Joslin Proteinuria Cohort that included 630 patients 
was assembled from among those who developed proteinuria while attending the Joslin 
Clinic between 1991 and 2004. The follow-up of this cohort is still ongoing. In the analysis 
of data for this study, the kidney phenotypes of patients at the enrollment into the Joslin 
Kidney Study were considered. Genotyping data were available for 244 patients with 
ESRD, 475 patients with proteinuria, 470 patients with microalbuminuria and 1,189 
patients with normoalbuminuria. 
SDRNT1BIO: The Scottish Diabetes Research Network Type 1 Bioresource is a 
prospective cohort study of 6,127 individuals from across Scotland. Participants aged 16 
years and over with a clinical diagnosis of T1D and insulin use within a year of onset were 
recruited from primary and secondary care across Scotland between 2010 and 2013. 
Serum, plasma, whole blood and urine samples were collected at study day allowing 
eGFR and albuminuria status to be obtained. Further retrospective and prospective 
biochemistry, co-morbidity and lifestyle data were linked from routine electronic health 
care records, providing serial estimates of renal status.13  
Steno: Patients with T1D attending the outpatient clinic at Steno Diabetes Center were 
invited to participate in a study of genetic risk factors for diabetes complications. T1D was 
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considered present if the age at onset of diabetes was ≤35 years and time to definite 
insulin therapy ≤1 year. DKD was defined by persistent albuminuria (>300 mg/24 h) in 
two out of three consecutive measurements, presence of retinopathy, and absence of 
other kidney or urinary tract disease. Absence of DKD (controls) was defined as persistent 
normoalbuminuria (<30 mg/24 h) after more than 15 years of T1D in patients not treated 
with ACE inhibitors or angiotensin-II receptor blockers. ESRD was defined as chronic 
dialysis or kidney transplantation.15 
Sweden: All patients with T1D were Swedish and diagnosed before 30 years of age. The 
patients with macroalbuminuria (urinary AER ≥ 200 µg min-1 in at least two consecutive 
overnight samples) were defined as case. The patients with AER <20 µg min-1 were 
considered as control.16 
UK-ROI: In the United Kingdom (UK) GoKinD, Warren 3 and All Ireland (UK-ROI) study, 
data were collected under a parallel protocol to that of the GoKinD study in the United 
States (see above). Briefly, all individuals are white with parents and grandparents born 
in the UK or Ireland and who had T1D diagnosed before 31 years of age. Cases have 
DKD diagnosed by the onset of proteinuria (>0.5 g/24 hr) >10 years since diagnosis of 
diabetes; controls are diabetic individuals without evidence of proteinuria (or 
microalbuminuria) >15 years after onset of diabetes.18 
WESDR: The Wisconsin Epidemiologic Study of Diabetic Retinopathy was an 
epidemiologic study of subjects with diabetes diagnosed before 30 years of age and 
taking insulin. Outcomes collected included proteinuria on a urine dipstick test.19 
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